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Abstract
Background: Although high-density lipoprotein (HDL) and non-HDL cholesterol have
opposite associations with coronary heart disease, multi-country reports of lipid trends
only use total cholesterol (TC). Our aim was to compare trends in total, HDL and non-
HDL cholesterol and the total-to-HDL cholesterol ratio in Asian and Western countries.
Methods: We pooled 458 population-based studies with 82.1 million participants in 23
Asian and Western countries. We estimated changes in mean total, HDL and non-HDL
cholesterol and mean total-to-HDL cholesterol ratio by country, sex and age group.
Results: Since 1980, mean TC increased in Asian countries. In Japan and South Korea,
the TC rise was due to rising HDL cholesterol, which increased by up to 0.17 mmol/L per
decade in Japanese women; in China, it was due to rising non-HDL cholesterol. TC de-
clined in Western countries, except in Polish men. The decline was largest in Finland and
Norway, at 0.4 mmol/L per decade. The decline in TC in most Western countries was
the net effect of an increase in HDL cholesterol and a decline in non-HDL cholesterol,
with the HDL cholesterol increase largest in New Zealand and Switzerland. Mean
total-to-HDL cholesterol ratio declined in Japan, South Korea and most Western coun-
tries, by as much as 0.7 per decade in Swiss men (equivalent to 26% decline in coro-
nary heart disease risk per decade). The ratio increased in China.
Conclusions: HDL cholesterol has risen and the total-to-HDL cholesterol ratio has de-
clined in many Western countries, Japan and South Korea, with only a weak correlation
with changes in TC or non-HDL cholesterol.
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Introduction
Blood cholesterol is one of the most important risk factors
for coronary heart disease (CHD).1–4 Population-level data
on blood cholesterol are an important input for planning
and evaluating the impacts of public health interventions
and treatment programmes on entire countries and com-
munities. Comparable data in different countries can help
to benchmark success in lowering cholesterol across coun-
tries and to understand the reasons behind different trends,
both those that were a result of active interventions and
unplanned secular changes in nutrition and health
behaviours.
Multi-country reporting of lipid trends has so far been
based on total cholesterol (TC).5,6 However, high-density
lipoprotein (HDL) and non-HDL or low-density lipopro-
tein (LDL) cholesterol have opposite associations with
CHD1,2 and can respond differently to changes in diet and
treatment. Currently, there are no comparable cross-
country data on lipid fractions, including LDL and HDL
cholesterol, and the total-to-HDL cholesterol ratio; only
studies in individual countries have reported such trends.7–27
To fill this important gap, we used population-based data to
analyse and compare long-term changes in TC, HDL and
non-HDL cholesterol, and the total-to-HDL cholesterol ra-
tio in Western and Asian countries over a period of more
than 30 years.
Methods
Primary outcomes
For this analysis, we used mean total, HDL and non-HDL
cholesterol and mean total-to-HDL cholesterol ratio as pri-
mary outcomes. The hazardous effects of blood cholesterol
on CHD were first established in the Framingham Study,
focusing on TC.28 However, physiological studies29 and
subsequent analyses of the Framingham Study30 found that
the fractions of blood cholesterol carried by different
lipoproteins and lipid ratios affect CHD risk differentially,
and at times in opposite directions. Pooled analyses of ob-
servational epidemiological studies have established that
CHD risk is associated directly with LDL and non-HDL
cholesterol and inversely with HDL cholesterol.1,2 As a re-
sult, lipid ratios such as the total-to-HDL cholesterol ratio,
which incorporates information on lipid fractions with op-
posite associations, have emerged as a particularly good
predictor of CHD risk in clinical and epidemiological
applications.1,2 Randomized clinical trials have also shown
that lowering LDL and non-HDL cholesterol lowers CHD
risk.31–34 In contrast, the results of observational studies
on HDL cholesterol have not been replicated in random-
ized trials or in Mendelian randomization studies.35–38
We used non-HDL cholesterol rather than LDL choles-
terol because most studies in our analysis had measured TC
and HDL cholesterol, from which non-HDL cholesterol
can be calculated by subtraction. In contrast, LDL choles-
terol was directly measured in only 13% of studies. When
LDL cholesterol is not directly measured, its estimation
requires data on triglycerides, which were available in only
61% of studies. Further, the most commonly used estima-
tion method, i.e. the Friedewald equation, can be inaccu-
rate.39 We found that non-HDL and LDL cholesterol were
correlated in studies with data on both variables (r¼ 0.93)
(Supplementary Figure 1, available as Supplementary data
at IJE online). Non-HDL cholesterol predicts CHD risk at
least as well as LDL cholesterol40,41 because it includes cho-
lesterol in LDL, lipoprotein(a), intermediate-density lipo-
protein, very-low-density lipoprotein and lipoprotein
remnants, and is thus a simple measure of cholesterol con-
tent within all atherogenic lipoproteins.
Countries analysed
Our analyses included Asian and Western countries that
had at least five population-based studies (or at least three
if the studies were nationally representative) in the Non-
Communicable Disease Risk Factor Collaboration (NCD-
Key Messages
• Total cholesterol (TC) has increased in Asian countries. In Japan and South Korea, the TC rise was largely due to an
increase in HDL cholesterol; in China, it was due to a rise in non-HDL cholesterol.
• The observed decline in TC in most Western countries was the net effect of an increase in HDL cholesterol and a de-
cline in non-HDL cholesterol.
• The total-to-HDL cholesterol ratio has declined in many Western countries, Japan and South Korea, with only a weak
correlation with changes in TC or non-HDL cholesterol.
• Countries’ comparative performance in reducing the risks associated with blood lipids is only partially captured by
trends in TC.
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RisC) database, as described below, with measurement of
total and HDL cholesterol over a period of at least 15 years
from 1970 onwards, with at least one data source after
2005. Twenty-one countries, listed below, met these
criteria:
• Nordic countries: Finland, Iceland and Norway.
• Eastern central Europe: Czech Republic, Lithuania,
Poland and Slovakia.
• Western central Europe: Belgium, Germany and
Switzerland.
• Southern Europe: France, Italy and Spain.
• High-income English-speaking countries: Australia,
Canada, New Zealand, UK and USA.
• East and southeast Asia: China, Japan and South Korea.
Two additional countries, Sweden and Thailand, had
sufficient data on TC but not on HDL cholesterol and
were included in TC analysis only.
Data sources
We used studies that had measured cholesterol in represen-
tative samples of the national population or of one or more
subnational regions and communities. We used a database
on cardiometabolic risk factors collated by NCD-RisC.
NCD-RisC is a worldwide network of health researchers
and practitioners whose aim is to document systematically
worldwide trends and variations in NCD risk factors.42–45
The database was collated through multiple routes for iden-
tifying and accessing data. We accessed publicly available
population-based measurement surveys [e.g. Demographic
and Health Surveys (DHS), Global School-based Student
Health Surveys (GSHS), the European Health Interview and
Health Examination Surveys (EHIS and EHES) and those
available via the Inter-university Consortium for Political
and Social Research (ICPSR)]. We requested, via the World
Health Organization (WHO) and its regional and country
offices, help with identification and access to population-
based surveys from ministries of health and other national
health and statistical agencies. Requests were also sent via
the World Heart Federation to its national partners. We
made similar requests to the co-authors of an earlier pooled
analysis of cardiometabolic risk factors5,46–48 and invited
them to reanalyse data from their studies and join NCD-
RisC. Finally, to identify major sources not accessed
through the above routes, we searched and reviewed pub-
lished studies as detailed previously42–44 and invited all eligi-
ble studies to join NCD-RisC.
Anonymized individual record data from sources in-
cluded in NCD-RisC were reanalysed by the Pooled
Analysis and Writing Group or by data holders according
to a common protocol. Within each survey, we included
participants aged 18 years and older who were not preg-
nant. We dropped participants with implausible choles-
terol levels (defined as TC <1.75 or >20 mmol/L; HDL
cholesterol <0.4 or >5 mmol/L; TC values < HDL values)
(<0.1% of all subjects). To ensure summaries were pre-
pared according to the study protocol, the Pooled Analysis
and Writing Group provided computer code to NCD-RisC
members who requested assistance. All submitted data
were checked by at least two independent members of the
Pooled Analysis and Writing Group. Questions and clarifi-
cations were discussed with NCD-RisC members and re-
solved before data were incorporated into the database.
Finally, we incorporated all nationally representative data
from sources that were identified but not accessed via the
above routes, by extracting summary statistics from pub-
lished reports. Data were extracted from published reports
only when reported by sex and in age groups no wider
than 20 years. We also used data from a previous global
data pooling study5 when such data had not been accessed
through the routes described.
All NCD-RisC members are asked periodically to re-
view the list of sources from their country, to suggest addi-
tional sources not in the database and to verify that the
included data meet the inclusion criteria listed below and
are not duplicates. The NCD-RisC database is continu-
ously updated through this contact with NCD-RisC mem-
bers and all the above routes. For this paper, we used data
from the NCD-RisC database for the 23 countries included
in the analysis, for years 1970–2018 and ages 40–79 years.
Data inclusion and exclusion
Data sources were included in the NCD-RisC lipids data-
base if:
• measured data on total, LDL, HDL cholesterol or trigly-
cerides were available;
• study participants were 10 years of age or older;
• data were collected using a probabilistic sampling
method with a defined sampling frame;
• data were from population samples at the national, sub-
national (i.e. covering one or more subnational regions,
more than three urban communities or more than five ru-
ral communities) or community level.
We excluded all data sources that included only hyper-
cholesterolemia or dyslipidaemia diagnosis history or med-
ication status without measurement of at least one of the
above biomarkers. We also excluded data sources on popu-
lation subgroups whose lipid profile may differ systemati-
cally from the general population, including:
• studies that had included or excluded people based on
their health status or cardiovascular risk;
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• studies whose participants were only ethnic minorities;
• specific educational, occupational or socio-economic
subgroups, with the exception noted below; and
• those recruited through health facilities, with the excep-
tion noted below.
We used data whose sampling frame was health insur-
ance schemes in countries where at least 80% of the popu-
lation were insured. Finally, we used data collected
through general practice and primary care systems in high-
income and central European countries with universal in-
surance because contact with the primary care systems
tends to be as good as, or better than, response rates for
population-based surveys.
We used data sources regardless of fasting status be-
cause the differences between fasting and non-fasting
measurements are negligible for our primary outcomes.49
From the CDC-NHLBI Lipid Standardization Program in
the 1950s, there has been an understanding of the need for,
and systematic efforts to achieve, standardization of lipid
measurements. The difference between any standardized
method and the CDC Reference method should be less
than 3% for TC and less than 5% for HDL cholesterol
(less than 10% before the mid-1990s).50 More than three-
quarters of the studies in our analysis participated in a lipid
standardization programme (Supplementary Table 1 and
Supplementary Figure 2, available as Supplementary data
at IJE online). A summary of data available by country is
shown in Supplementary Table 2, available as
Supplementary data at IJE online, and characteristics of
each study are shown in Supplementary Table 1, available
as Supplementary data at IJE online.
We extracted data for ages 40–79 years because people
aged below 40 years have a lower cardiovascular risk and
because data in older ages were available in fewer surveys.
CHD mortality increases with age whereas hazard ratios
for the effects of cholesterol on CHD decrease with age.1,2
As a result, a larger share of CHD deaths are attributable
to elevated cholesterol in middle-older ages, but the num-
ber of cholesterol-attributable deaths continues to increase
with age.4 We present results for 40–59 years as the pri-
mary analysis because data on these age groups were avail-
able for all countries included in the analysis. To
investigate the role of age in our findings, we compared
results for ages 40–59 years to those of 60–79 years in
countries with data for the entire age range of 40–79 years.
Statistical methods
For each study, we calculated mean total, HDL and non-
HDL cholesterol and mean total-to-HDL cholesterol ratio by
sex and 10-year age groups. The total-to-HDL cholesterol ra-
tio was calculated using individual records before averaging
for each sex and age group. All analyses incorporated appro-
priate complex survey design and survey sample weights in
calculating age- and sex-specific means.
For each primary outcome and for each country, sex
and age group, we calculated average annual change over
the entire period of data availability by fitting a linear re-
gression with the study-specific means as the dependent
variable and year as the independent variable. Each data
point was weighted by the inverse of the square of its stan-
dard error, so that larger studies had more influence on the
estimated change. We multiplied the slope of the fitted line
by 10 to calculate average change per decade. We also
used the fitted line to estimate total, HDL and non-HDL
cholesterol and the total-to-HDL cholesterol ratio values
for a consistent period of 1980–2015 for all countries. For
countries with data starting before 1980 and/or ending af-
ter 2015, this is equivalent to using the fitted line to inter-
polate for 1980 and/or 2015; for those with data starting
after 1980 and/or ending before 2015, values for 1980
and/or 2015 were extrapolated using the fitted line. In a
sensitivity analysis, we fitted a non-linear (LOESS) regres-
sion to examine by how much our results are influenced by
use of linear trend. For each primary outcome and for each
country, results were calculated by 10-year age groups,
separately for men and women, and then age-standardized
into two age bands (40–59 and 60–79 years) by taking a
weighted average of age-specific results using weights from
the WHO standard population. Analyses were performed
in R version 3.4.0 (The R Foundation for Statistical
Computing).
Results
Data availability
We used 438 population-based studies, collected from 1970 to
2018 in 21 countries that met our inclusion criteria for TC as
well as lipid fractions. An additional 20 studies were used for
analysis of TC in two additional countries (Thailand and
Sweden). Together, these studies included blood lipid measure-
ments in 82.1 million participants, 79million of whom were
aged 40–79years. The number of data sources ranged from 5
in Slovakia to 56 in Japan. The average time between the first
and last studies in a country was around three decades. For the
primary analysis, we used 425 studies with data for ages 40–
59years. All these 425 studies had data on TC. In the 21 coun-
tries included in the analysis of lipid fractions, 368 of 405 stud-
ies (90.9%) had data on HDL cholesterol and 367 (90.6%)
on the total-to-HDL cholesterol ratio. Details of data availabil-
ity by country and characteristics of each study are shown in
Supplementary Tables 1 and 2, available as Supplementary
data at IJE online.
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Total cholesterol
Mean TC declined in men and women aged 40–59 years in
most Western countries, except in Polish men, whose TC
was about the same at the beginning and end of the analysis
period (Figure 1). The absence of long-term change in
Poland was a result of a rise in mean TC until the late
1990s, followed by a decline (Supplementary Figure 3,
available as Supplementary data at IJE online). In both
sexes, the decline was larger in Nordic countries and central
Europe than in English-speaking countries and southern
Europe. The TC decline in men ranged from<0.1 mmol/L per
decade in Lithuania, New Zealand and France to
0.4 mmol/L per decade in Norway, Finland and Belgium.
In women, the range was from <0.1 mmol/L per decade in
Poland, France and Italy to 0.4 mmol/L per decade in
Finland, Norway and Belgium. TC increased in all four
Asian countries, with the largest increase in China and
Thailand, by 0.3 mmol/L per decade. Despite this rise,
Chinese women (but not men) still had the lowest estimated
mean TC of all 23 countries in 2015 (5.0 mmol/L)
(Supplementary Figure 4, available as Supplementary data
at IJE online). The highest mean TCs in 2015 were those in
Lithuanian and French men and Thai women, all above
5.7 mmol/L.
HDL and non-HDL cholesterol
Among the three Asian countries with data on lipid frac-
tions, the rise in mean TC in Japan and South Korea was
largely due to an increase in mean HDL cholesterol, which,
among Japanese and South Korean women, was offset
partly by a decline in non-HDL cholesterol (Figure 2). The
rise in HDL cholesterol ranged from 0.04 mmol/L per de-
cade in South Korean men to 0.17 mmol/L per decade in
Japanese women. In contrast, the TC rise in China was due
to an increase in non-HDL cholesterol whereas HDL cho-
lesterol remained unchanged in women and increased
slightly in men.
The decline in mean TC in many Western countries was
the net effect of a decline in non-HDL cholesterol and an in-
crease in HDL cholesterol (Figure 2). The key exceptions
were men and women in Germany and Norway, and men
in the Czech Republic and Slovakia, where both HDL and
non-HDL cholesterol declined. Similar to TC, mean non-
HDL cholesterol generally declined more in Nordic coun-
tries and central Europe than in English-speaking and
southern European countries. The largest rise in mean HDL
cholesterol occurred in New Zealand and Switzerland, by
0.10–0.15 mmol/L per decade in the two sexes.
The change in mean HDL cholesterol and change in
mean non-HDL cholesterol were not correlated (r¼ –0.004
for men and –0.07 for women) (Figure 3). In 2015, the low-
est levels of mean non-HDL cholesterol were those in China
and Belgium for men (3.7 mmol/L) and in Iceland for
women (3.3 mmol/L) (Supplementary Figure 5, available as
Supplementary data at IJE online). The highest were in
France: 4.4 mmol/L for men and 4.0 mmol/L for women.
Total-to-HDL cholesterol ratio
Mean total-to-HDL cholesterol ratio declined in most
Western countries, by as much as 0.7 per decade in Swiss
men and 0.5 per decade in New Zealand and Swiss
women (Figure 4). The ratio changed little in Slovakian
men. In Asia, China experienced a rise in mean total-to-
HDL cholesterol ratio because of the above-mentioned
non-favourable changes in lipid fractions. In contrast, de-
spite the rise in mean TC, the total-to-HDL cholesterol ra-
tio declined in Japan and South Korea because HDL
cholesterol increased by a larger proportion than did TC.
The change in mean total-to-HDL cholesterol ratio was
only moderately correlated with the change in mean TC
(correlation coefficient¼ 0.52 for men and 0.53 for
women) (Figure 5). Japan and South Korea were particu-
larly notable in having had a rise in TC but a decline in the
total-to-HDL cholesterol ratio, while Norway, Germany
and men in Slovakia had declining TC with little change in
the total-to-HDL cholesterol ratio. In 2015, the lowest ra-
tio was that of Japanese women (2.9) and Japanese men
(3.7) (Supplementary Figure 6, available as Supplementary
data at IJE online).
Results for people aged 60–79 years
Results in people aged 60–79 years were moderately to
strongly correlated with those aged 40–59 years (Figure 6
and Supplementary Figure 3, available as Supplementary
data at IJE online). In virtually all countries, mean TC,
non-HDL cholesterol and total-to-HDL cholesterol ratio
declined more in these older age groups than in people
aged 40–59 years. The decline advantage in older ages was
particularly evident for Australia and the UK, where
women and men aged 60–79 years experienced a decline in
non-HDL cholesterol twice as large as those aged 40–
59 years. The change in mean HDL cholesterol was larger
in older ages in some countries and smaller in others, indi-
cating that its change may be due to factors that are at least
partly different from those affecting non-HDL cholesterol.
Discussion
By conducting a comparative analysis of changes in TC
and lipid fractions and ratios, we found varying rates of
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Figure 1. Change per decade in mean total cholesterol by sex in people aged 40–59 years. Results for each country apply to its period of total choles-
terol data availability (Supplementary Table 2, available as Supplementary data at IJE online). See Supplementary Table 3, available as
Supplementary data at IJE online, for numerical results and 95% confidence intervals.
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Figure 2. Change per decade in mean (A) HDL and (B) non-HDL cholesterol by sex in people aged 40–59 years. Results for each country apply to its pe-
riod of HDL and non-HDL cholesterol data availability (Supplementary Table 2, available as Supplementary data at IJE online). See Supplementary
Table 4, available as Supplementary data at IJE online, for numerical results and 95% confidence intervals.
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Figure 2. Continued.
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decline in TC in Western countries and a rise in Asian coun-
tries, leading to an overall convergence in TC among these
countries. Underlying this convergence were more heteroge-
neous trends in HDL and non-HDL cholesterol, with HDL
cholesterol rising in more than half the countries included
in the analysis. The diverse trends in HDL and non-HDL
cholesterol resulted in substantial cross-country variation in
trends for mean total-to-HDL cholesterol ratio, with the ra-
tio declining in most countries, but increasing in China.
Our findings on TC trends are largely consistent with
prior multi- and single-country reports. Differences from
previous studies—e.g. in some countries that participated
in the MONICA Project,6 Poland21 and Switzerland24—
mostly arise because our study covered a longer period and
used a larger number of data sources. Fewer studies have
reported trends in lipid fractions and, to our knowledge,
none has done so consistently across countries. Studies that
have reported trends in lipid fractions for a period longer
than 15 years8,11,16,18–20,25–27 have found changes in non-
HDL cholesterol (or in LDL cholesterol for some studies)
that were consistent with our results.
The observed decline in non-HDL cholesterol in
Western countries is likely to have been mostly due to
changes in diet—especially the replacement of saturated
with unsaturated fats and reduction in trans-fats.8,20,51
Statins have also been widely used in high-risk patients
since the 1990s26,52 and may have helped lower the popu-
lation mean, especially in older ages. In the majority of
countries in our analysis, the decline in non-HDL choles-
terol started in the 1980s, before statins were widely used.
Further, we observed a decline in non-HDL cholesterol in
men and women aged 40–49 years, among whom statin
use is relatively low. Nonetheless, the higher use of statins
in older ages may at least partly explain the larger decline
in non-HDL cholesterol observed in those aged 60–
79 years.26,53
Dietary changes in Western countries contrast with the
substantial rise in consumption of animal fats in China,54
where statin use remains low.55 Focusing on non-HDL
cholesterol alone, however, conceals important changes in
HDL cholesterol and the total-to-HDL cholesterol ratio.
Although HDL cholesterol does not have a dominant non-
genetic determinant, it is affected adversely (i.e. is lower)
by adiposity, type 2 diabetes, intake of trans-fats and car-
bohydrates, especially those with a high glycaemic index,
smoking and the use of some drugs (e.g. b-blockers, ana-
bolic steroids).56–63 Conversely, increases in physical activ-
ity, alcohol consumption, total fat intake and oestrogens
increase HDL cholesterol.56,57,59–63 A decrease in carbohy-
drate intake and an increase in fat intake may have con-
tributed to the increase in HDL cholesterol in Japan,64,65
South Korea62,66 and Switzerland,67 whereas declines in
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Figure 3. Change per decade in mean non-HDL vs HDL cholesterol in people aged 40–59 years. Results for each country apply to its period of HDL and
non-HDL cholesterol data availability (Supplementary Table 2, available as Supplementary data at IJE online). See Supplementary Table 4, available
as Supplementary data at IJE online, for numerical results and 95% confidence intervals. AUS, Australia; BEL, Belgium; CAN, Canada; CHE,
Switzerland; CHN, China; CZE, Czech Republic; DEU, Germany; ESP, Spain; FIN, Finland; FRA, France; GBR, United Kingdom; ISL, Iceland; ITA, Italy;
JPN, Japan; KOR, South Korea; LTU, Lithuania; NOR, Norway; NZL, New Zealand; POL, Poland; SVK, Slovakia; USA, United States of America.
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Figure 4. Change per decade in mean total-to-HDL cholesterol ratio by sex in people aged 40–59 years. Results for each country apply to its period of
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carbohydrate intake and smoking may have contributed to
the rise in the USA26 and some other countries. In contrast,
an increase in carbohydrate intake67 and a decline in alco-
hol consumption68 have been observed in Germany, where
we observed a slight decline in HDL cholesterol. The de-
cline in smoking in most Western countries may have also
contributed to the observed increase in HDL cholesterol.
The strengths of our study include its novel scope of
comparing lipid fractions across countries and using a
large number of high-quality population-based studies
over more than three decades. Such comprehensive data
allowed us to document a significant rise in HDL choles-
terol, which is considered difficult to change, in a number
of Western and Asian countries as a contributor to the de-
cline in the total-to-HDL cholesterol ratio. A multi-
country study, such as ours, is also affected by some limita-
tions. Clinical trials of drugs that raise HDL cholesterol
and genetic and epidemiologic studies have shown the
complexity of the relationship between HDL cholesterol,
HDL particles and cardiovascular and other dis-
eases.35,37,38,69 We used HDL and non-HDL cholesterol
because there were significantly more data available than
on LDL cholesterol and because the total-to-HDL choles-
terol ratio is commonly used in clinical practice. We did
not analyse trends in different HDL particles because this
information is not available in most population-based
health surveys and because it is not commonly used to
make clinical decisions. For the same reason, we also did
not analyse emerging lipid markers such as apolipoprotein
B and apolipoprotein A-I.56,70 We used the average change
per decade, estimated in a linear model, which has the ad-
vantage of being parsimonious, but trends in some coun-
tries may be non-linear. When we fitted a non-linear
LOESS regression (Supplementary Figure 3, available as
Supplementary data at IJE online), the estimated average
decadal change was similar to the estimates from the linear
model in most countries. Almost 80% of the studies in our
analysis had used enzymatic methods for measuring TC,
which have been well standardized since at least the 1980s.
Although methods to measure HDL cholesterol have
evolved over time—chemical precipitation methods to sep-
arate HDL and, more recently, homogeneous assays71—
more than three-quarters of the studies in our analysis par-
ticipated in a lipid standardization programme
(Supplementary Figure 2, available as Supplementary data
at IJE online). A rise in HDL cholesterol was also seen in
countries and over periods where measurement methods
did not change. Nonetheless, the observed changes in HDL
cholesterol in some countries were in the same order of
magnitude to which laboratories’ accuracies can be stan-
dardized. Although most studies had measured cholesterol
in serum, 11% had used plasma. Adjusting for plasma-
serum differences had little impact on our results and did
not change our conclusions (Supplementary Figure 7,
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available as Supplementary data at IJE online) because
cholesterol measured in plasma and serum differ by only
about 3%.50 Finally, although all our data were from sam-
ples of the general population, 40% came from
community-based studies. In some countries, community-
based studies came from the same community in different
years; in others, studies were from different parts of the
same country, which led to additional variability in data
and uncertainty in the estimated change. Our key findings
on lipid fractions were also seen where the data sources
covered the entire country or large parts of it. In 11 coun-
tries, our analysis was limited to ages 40–59 years because
fewer studies had data in people older than 60 years of age,
for whom non-HDL cholesterol may have declined more
due to the use of statins, as indicated by the results in the
10 countries with data covering ages 40–79 years.
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Whereas early epidemiological studies used TC as a
marker of cardiovascular risk in individuals and popula-
tions,72 our study shows that the populations of Asian
and Western countries have experienced large and hetero-
geneous changes in lipid fractions, including substantial
increases in HDL cholesterol and substantial falls in non-
HDL cholesterol. In the best-performing countries, those
in Europe and New Zealand, the total-to-HDL choles-
terol ratio has declined by 1.5–2.3 since the 1980s, which
is equivalent to a 48–63% reduction in the risk of CHD.1
In Japan and South Korea, the total-to-HDL cholesterol
ratio has declined, which provides a simple explanation
for the apparent paradox of declining CHD while TC in-
creased.73 A key implication of our findings is the
need for national surveillance systems that, consistently
with modern clinical practice, measure relevant lipid
fractions and their determinants, including diet, health
behaviours such as smoking and alcohol use, and use of
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statins to support the design and evaluation of public-
health programmes.
Despite the improvements that we have documented,
the populations of all countries analysed here would bene-
fit from lower non-HDL cholesterol and total-to-HDL
cholesterol ratios. In China, which had some of the lowest
recorded non-HDL cholesterol and TC levels a few decades
ago, changes in diet and relatively low treatment coverage
have led to unfavourable trends in lipid profiles. Therefore,
population-based policies and targeted interventions to im-
prove nutrition and enhance treatment are still needed in
all these countries and should be designed and evaluated
based on their impacts on all health-relevant lipid fractions
and on the corresponding health outcomes.
Supplementary data
Supplementary data are available at IJE online.
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Supplementary Table 1: Data sources used in the analysis. 
3
Male Female Male Female Male Female Male Female Total cholesterol
HDL cholesterol
(separation and quantification 
methods)
1 Australia 1980 Risk Factor Prevalence Study National 40-59 40-59 1,372 1,418 1,279 1,330 1,278 1,330 LRC method
Heparin-Manganese method; 
LRC method
Plasma Yes (CDC/CRMLN)
2 Australia 1983 MONICA, Newcastle Subnational 40-59 40-59 775 788 736 772 735 765 Extraction/Enzymatic
Heparin-Manganese method; 
Extraction
Plasma Yes (WHO-LRC)
3 Australia 1983 Risk Factor Prevalence Study National 40-59 40-59 1,754 1,796 1,739 1,807 1,722 1,785 LRC method
Heparin-Manganese method; 
LRC method
Plasma Yes (CDC/CRMLN)
4 Australia 1988-1989 Dubbo Study of Australian Elderly Community 60-79 60-79 807 1,084 805 1,084 805 1,084 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (CDC/CRMLN)
5 Australia 1988-1989 MONICA, Newcastle Subnational 40-59 40-59 416 411 415 411 415 411 Enzymatic PEG 6000 method; Enzymatic Serum Yes (WHO-LRC)
6 Australia 1989 Risk Factor Prevalence Study National 40-69 40-69 2,555 2,577 2,555 2,577 2,555 2,577 Enzymatic PEG 6000 method; Enzymatic Plasma Yes (WHO-LRC)
7 Australia 1992-1993 Australia Longitudinal Study of Ageing Community 70-79 70-79 341 316 340 316 340 316 Unknown Unknown Serum Unknown
8 Australia 1994 MONICA, Newcastle Subnational 40-59 40-59 383 422 381 421 381 421 Enzymatic PEG 6000 method; Enzymatic Serum Yes (WHO-LRC)
9 Australia 1994 MONICA, Perth inner Community 40-59 40-59 192 185 192 185 192 185 Enzymatic
Heparin-Manganese method; 
Enzymatic
Plasma Yes (WHO-LRC)
10 Australia 1994 MONICA, Perth outer Community 40-59 40-59 206 212 206 212 206 212 Enzymatic
Heparin-Manganese method; 
Enzymatic
Plasma Yes (WHO-LRC)
11 Australia 1999-2000
The Australian Diabetes, Obesity and 
Lifestyle Study 1999-2000
National 40-79 40-79 3,822 4,559 3,820 4,558 3,820 4,558 Enzymatic Unknown; Enzymatic Serum Yes (other)
12 Australia 1999-2003 North West Adelaide Health Study Community 40-79 40-79 1,312 1,462 1,312 1,462 1,311 1,462 Enzymatic
Homogeneous assay (Antibody, 
two reagents)
Serum Yes (other)
13 Australia 2004-2005
The Australian Diabetes, Obesity and 
Lifestyle Study 2004-2005
National 40-79 40-79 2,480 2,986 2,480 2,984 2,480 2,984 Enzymatic
Homogeneous assay (Dextran 
sulphate-Magnesium + PEG-
coupled enzymes)
Serum Yes (other)
14 Australia 2004-2006 North West Adelaide Health Study Community 40-79 40-79 1,141 1,304 1,141 1,304 1,141 1,304 Enzymatic
Homogeneous assay (Antibody, 
two reagents)
Serum Yes (other)
15 Australia 2008-2010 North West Adelaide Health Study Community 40-79 40-79 935 1,070 935 1,070 935 1,070 Enzymatic
Homogeneous assay (Antibody, 
two reagents)
Serum Yes (other)
16 Australia 2011-2012 Australian Health Survey National 40-79 40-79 3,023 3,590 3,023 3,590 3,023 3,590 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Unknown
17 Australia 2012
The Australian Diabetes, Obesity and 
Lifestyle Study 2012
National 40-79 40-79 1,863 2,342 1,863 2,342 1,863 2,342 Enzymatic Unknown; Enzymatic Serum Yes (other)
18 Belgium 1984-1985
Belgian Interuniversity Research on 
Nutrition and Health
National 40-69 40-69 3,584 3,135 3,542 3,121 3,541 3,120 Extraction
Heparin-Manganese method; 
Extraction
Serum Yes (CDC/CRMLN)
19 Belgium 1985-1987 MONICA, Charleroi Community 40-59 40-59 173 144 172 144 172 144 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
20 Belgium 1985-1987 MONICA, Ghent Community 40-59 40-59 266 221 262 220 262 220 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
21 Belgium 1985-1990
Flemish Study on Environment, Genes 
and Health Outcomes
Community 40-79 40-79 408 403 292 292 292 292 Enzymatic PEG 6000 method; Enzymatic Serum Yes (other)
Age range as used 
for the analysis
Country Data years Survey/Study name/Citation
Level of 
representati-
veness
Note
Sample size
(Total cholesterol)
Sample size
(HDL cholesterol)
Method used to measure
Whether 
lipids were 
measured in 
serum or 
plasma 
samples
Participating to a 
lipid standardisation 
programme or 
quality control 
schemes
Sample size
(Non-HDL 
cholesterol)
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22 Belgium 1987-1990 MONICA, Charleroi Community 40-59 40-59 161 140 160 140 160 140 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
23 Belgium 1988-1990 MONICA, Ghent Community 40-59 40-59 207 227 207 227 207 227 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
24 Belgium 1990-1993 MONICA, Charleroi Community 40-59 40-59 151 148 151 144 151 144 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
25 Belgium 1990-1992 MONICA, Ghent Community 40-59 40-59 236 237 236 237 236 237 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
26 Belgium 1991-1994
Flemish Study on Environment, Genes 
and Health Outcomes
Community 40-79 40-79 281 288 280 288 280 288 Enzymatic PEG 6000 method; Enzymatic Serum Yes (other)
27 Belgium 1996-1998
Flemish Study on Environment, Genes 
and Health Outcomes
Community 40-79 40-79 188 183 186 183 186 183 Enzymatic
Homogeneous assay (Antibody, 
two reagents)
Serum Yes (other)
28 Belgium 1998
Flemish Study on Environment, Genes 
and Health Outcomes
Community 40-79 40-79 276 306 276 306 276 306 Enzymatic
Homogeneous assay (Antibody, 
two reagents)
Serum Yes (other)
29 Belgium 1999-2001
Flemish Study on Environment, Genes 
and Health Outcomes
Community 40-79 40-79 122 130 122 130 122 130 Enzymatic
Homogeneous assay (Antibody, 
two reagents)
Serum Yes (other)
30 Belgium 2001
Flemish Study on Environment, Genes 
and Health Outcomes
Community 40-69 40-69 121 109 121 109 121 109 Enzymatic
Homogeneous assay (Antibody, 
two reagents)
Serum Yes (other)
31 Belgium 2002-2003
Flemish Study on Environment, Genes 
and Health Outcomes
Community 40-79 40-79 92 102 92 102 92 102 Enzymatic
Homogeneous assay (Antibody, 
two reagents)
Serum Yes (other)
32 Belgium 2003 The European Male Ageing Study Community 40-79 444 443 443 Unknown Unknown Unknown Unknown
33 Belgium 2002-2005
Flemish Study on Environment, Genes 
and Health Outcomes
Community 40-79 40-79 261 264 260 264 260 264 Enzymatic
Homogeneous assay (Antibody, 
two reagents)
Serum Yes (other)
34 Belgium 2005-2008
Flemish Study on Environment, Genes 
and Health Outcomes
Community 40-79 40-79 323 347 323 347 323 347 Enzymatic
Homogeneous assay (Antibody, 
two reagents)
Serum Yes (other)
35 Belgium 2008 The European Male Ageing Study Community 40-79 359 360 358 Unknown Unknown Unknown Unknown
36 Belgium 2009-2013
Flemish Study on Environment, Genes 
and Health Outcomes
Community 40-79 40-79 256 272 255 271 255 271 Enzymatic
Homogeneous assay (2 assays 
used: Antibody, two reagents 
and Dextran sulphate-
Magnesium + PEG-coupled 
enzymes)
Serum Yes (other)
37 Belgium 2010-2015
Flemish Study on Environment, Genes 
and Health Outcomes
Community 40-79 40-79 287 279 287 279 287 279 Enzymatic
Homogeneous assay (2 assays 
used: Antibody, two reagents 
and Dextran sulphate-
Magnesium + PEG-coupled 
enzymes)
Serum Yes (other)
38 Canada 1985-1988 MONICA, Halifax Community 40-59 40-59 240 235 238 235 238 235 Enzymatic
Heparin-Manganese method; 
Enzymatic
Serum Yes (WHO-LRC)
39 Canada 1986-1992 Canada Heart Health Survey National 40-69 40-69 3,452 3,394 3,428 3,370 3,427 3,370 LRC method/Enzymatic
Heparin-Manganese method; 
Enzymatic
Plasma Yes (CDC/CRMLN)
40 Canada 1995 MONICA, Halifax Community 40-59 40-59 143 155 143 155 143 155 Enzymatic
Dextran sulphate-Magnesium 
method; Enzymatic
Serum Yes (WHO-LRC)
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41 Canada 1995-1997
Canadian Multicentre Osteoporosis 
Study (CaMos)
Community 40-79 40-79 133 344 133 344 133 344 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum No
42 Canada 2005-2008
Canadian Multicentre Osteoporosis 
Study (CaMos)
Subnational 40-79 40-79 528 1,288 528 1,288 528 1,288 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum No
43 Canada 2007-2009
Canadian Health Measures Survey, 
Cycle 1
National 40-79 40-79 1,104 1,183 1,104 1,183 1,104 1,183 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (other)
44 Canada 2009-2011
Canadian Health Measures Survey, 
Cycle 2
National 40-79 40-79 1,120 1,180 1,122 1,181 1,120 1,180 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (other)
45 Canada 2012-2013
Canadian Health Measures Survey, 
Cycle 3
National 40-79 40-79 1,050 1,062 1,050 1,062 1,050 1,062 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (CDC/CRMLN)
46 Canada 2014-2015
Canadian Health Measures Survey, 
Cycle 4
National 40-79 40-79 1,020 1,027 1,019 1,027 1,019 1,027 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (CDC/CRMLN)
47 China 1983 Sino-MONICA Shanghai Community 40-59 40-59 406 398 404 397 404 397 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
48 China 1984-1985 Sino-MONICA Beijing Community 40-59 40-59 441 445 440 443 440 443 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
49 China 1988 Sino-MONICA Hebei Community 40-59 356 345 345 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
50 China 1988 Sino-MONICA Heilongjiang Community 40-59 40-59 432 426 432 426 432 426 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
51 China 1988 Sino-MONICA Henan Community 40-59 40-59 186 240 186 240 186 240 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
52 China 1988 Sino-MONICA Neimenggu Community 40-59 40-59 215 207 208 207 208 207 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
53 China 1988 Sino-MONICA Sichuan Community 40-59 40-59 169 186 169 186 169 186 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
54 China 1988 Sino-MONICA Shandong Community 40-59 40-59 87 94 87 94 87 94 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
55 China 1986-1989 Sino-MONICA Shanghai Community 40-59 40-59 409 441 409 441 409 441 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
56 China 1988-1989 Sino-MONICA Beijing Community 40-59 40-59 358 466 355 466 355 465 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
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57 China 1989 Sino-MONICA Fujian Community 40-59 40-59 92 88 92 88 92 88 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
58 China 1988-1989 Sino-MONICA Jilin Community 40-59 40-59 211 234 201 220 201 220 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
59 China 1989 Sino-MONICA Jiangsu Community 40-59 40-59 189 184 189 184 189 184 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
60 China 1988-1989 Sino-MONICA Jiangxi Community 40-59 40-59 187 205 187 205 187 205 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
61 China 1988-1989 Sino-MONICA Liaoning Community 40-59 40-59 360 381 360 381 360 380 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
62 China 1991 Sino-MONICA Shanghai Community 40-59 40-59 384 441 384 441 384 441 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
63 China 1992-1993 Anzhen 02 Cohort Study Community 40-59 40-59 1,435 1,271 1,430 1,270 1,430 1,268 Unknown Unknown Serum Unknown
64 China 1991-1992 Fangshan Cohort Study Community 40-79 40-79 163 366 153 351 151 347 Unknown Unknown Serum Unknown
65 China 1992 Huashan Study Community 40-69 40-69 398 436 395 434 395 434 Unknown Unknown Serum Unknown
66 China 1992 Sino-MONICA Sichuan Community 40-59 40-59 424 311 424 311 424 311 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
67 China 1993 Sino-MONICA Anhui Community 40-59 40-59 85 84 85 84 85 84 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
68 China 1993 Sino-MONICA Beijing Community 40-59 40-59 306 435 306 435 306 435 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
69 China 1993 Sino-MONICA Jiangsu Community 40-59 40-59 261 171 261 171 261 171 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
70 China 1993 Sino-MONICA Liaoning Community 40-59 40-59 265 237 265 237 265 237 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
71 China 2000-2001
The International Collaborative Study of 
Cardiovascular Disease in ASIA
National 40-69 40-69 4,220 4,616 4,218 4,615 4,215 4,612 Enzymatic
Dextran sulphate-Magnesium 
method; Enzymatic
Serum Yes (CDC/CRMLN)
72 China 2002
China National Nutrition and Health 
Survey
National 40-79 40-79 9,719 11,194 9,741 11,223 9,715 11,190 Enzymatic Homogeneous assay Plasma Yes (CDC/CRMLN)
73 China 2006 Beijing Eye Study Community 50-79 50-79 354 559 361 567 354 558 Enzymatic
Homogeneous assay (PEG-
coupled enzymes)
Serum Unknown
74 China 2008
China Health and Retirement 
Longitudinal Study (CHARLS), pilot 
survey
Subnational 50-79 50-79 347 358 336 357 336 355 Cardiocheck Cardiocheck Capillary Unknown
75 China 2007-2008
China National Diabetes and Metabolic 
Disorders Study; Yang et al., Circulation 
2012; 125: 2212-21
National 40-79 40-79 6,970 10,538 6,970 10,538 6,970 10,538 Enzymatic Unknown Serum Yes (other) 1
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76 China 2009 China Health and Nutrition Study National 40-79 40-79 1,885 2,174 1,880 2,167 1,879 2,167 Enzymatic
Homogeneous assay (alpha-
Cyclodextrin + PEG-coupled 
enzymes)
Serum Yes (other) 4
77 China 2010
China Noncommunicable  Disease 
Surveillance
National 40-79 40-79 20,047 25,259 20,062 25,329 19,998 25,232 Enzymatic Unknown; Enzymatic Serum Unknown
78 China 2011 Beijing Eye Study Community 50-79 50-79 406 606 406 606 406 606 Enzymatic
Homogeneous assay (PEG-
coupled enzymes)
Serum Unknown
79 China 2011-2012
China Health and Retirement 
Longitudinal Study (CHARLS), baseline 
survey
National 50-79 50-79 1,584 1,858 1,583 1,859 1,580 1,856 Enzymatic
Homogeneous assay (alpha-
Cyclodextrin + PEG-coupled 
enzymes)
Plasma Yes (other)
80 China 2012-2013 The Kailuan Study Community 40-79 40-79 40,331 12,057 40,192 12,037 40,177 12,035 Enzymatic Homogeneous assay Serum Unknown
81 China 2014-2015 The Kailuan Study Community 40-79 40-79 31,110 9,335 31,060 9,332 31,034 9,328 Enzymatic Homogeneous assay (Catalase) Plasma Yes (CDC/CRMLN)
82 Czech Republic 1985 MONICA, Czech Republic National 40-59 40-59 634 651 634 651 634 651 Enzymatic
Updated phosphotungstate-
Magnesium method after the 
Boehringer-Ms (PTA 543004); 
Enzymatic
Serum Yes (WHO-LRC)
83 Czech Republic 1988 MONICA, Czech Republic National 40-59 40-59 702 705 702 705 701 705 Enzymatic
Updated phosphotungstate-
Magnesium method after the 
Boehringer-Ms (PTA 543004); 
Enzymatic
Serum Yes (WHO-LRC)
84 Czech Republic 1992 MONICA, Czech Republic National 40-59 40-59 602 615 597 613 597 613 Enzymatic
Updated phosphotungstate-
Magnesium method after the 
Boehringer-Ms (PTA 543004); 
Enzymatic
Serum Yes (WHO-LRC)
85 Czech Republic 1997-1998 Czech post-MONICA National 40-59 40-59 899 987 894 987 894 987 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (CDC/CRMLN)
86 Czech Republic 2000-2001 Czech post-MONICA National 40-59 40-59 944 946 940 941 940 941 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (CDC/CRMLN)
87 Czech Republic 2006-2009 Czech post-MONICA National 40-59 40-59 934 1,022 922 1,003 922 1,003 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (CDC/CRMLN)
88 Czech Republic 2015-2018 MONICA National 40-59 40-59 673 761 672 760 672 760 Enzymatic
Homogeneous assay (Dextran 
sulphate-Magnesium + PEG-
coupled enzymes)
Serum Yes (CDC/CRMLN)
89 Finland 1972 North Karelia project Subnational 40-59 40-59 3,033 3,328 Direct Serum No
90 Finland 1977 North Karelia project Subnational 40-59 40-59 3,015 3,315 Direct Serum Yes (other)
91 Finland 1982
MONICA, North 
Karelia/Kuopio/Turku/Loimaa
Subnational 40-59 40-59 2,346 2,349 2,342 2,348 2,342 2,348 Enzymatic
Dextran sulphate-Magnesium 
method; Enzymatic
Serum Yes (WHO-LRC)
92 Finland 1987
MONICA, North 
Karelia/Kuopio/Turku/Loimaa
Subnational 40-59 40-59 1,553 1,663 1,552 1,663 1,552 1,663 Enzymatic
Dextran sulphate-Magnesium 
method; Enzymatic
Serum Yes (WHO-LRC)
93 Finland 1992 The National FINRISK Study Subnational 40-59 40-59 1,529 1,589 1,529 1,589 1,529 1,589 Enzymatic
Dextran sulphate-Magnesium 
method; Enzymatic
Serum Yes (WHO-LRC)
94 Finland 1997 The National FINRISK Study National 40-69 40-69 1,835 1,949 1,833 1,949 1,833 1,949 Enzymatic
Dextran sulphate-Magnesium 
method; Enzymatic
Serum Yes (WHO-LRC)
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95 Finland 1996-1998 Savitaipale Study, Baseline Community 40-59 40-59 443 458 442 457 442 457 Enzymatic
Homogeneous assay (Dextran 
sulphate-Magnesium + PEG-
coupled enzymes)
Serum Yes (other)
96 Finland 2000
Viiri et al., Atherosclerosis 2005; 179: 
161-7
Community 50-59 74 Enzymatic Serum Unknown
97 Finland 2000
Viiri et al., Atherosclerosis 2005; 179: 
161-7
Community 50-59 101 Enzymatic Serum Unknown
98 Finland 2000
Viiri et al., Atherosclerosis 2005; 179: 
161-7
Community 50-59 42 Enzymatic Serum Unknown
99 Finland 2000-2001 Health 2000 Survey National 40-79 40-79 1,439 1,551 1,439 1,551 1,439 1,551 Enzymatic
Homogeneous assay (Dextran 
sulphate-Magnesium + PEG-
coupled enzymes)
Serum Yes (other)
100 Finland 2002 The National FINRISK Study National 40-69 40-69 1,597 1,831 1,596 1,831 1,596 1,831 Enzymatic
Homogeneous assay (PEG-
coupled enzymes)
Serum Yes (CDC/CRMLN)
101 Finland 2007 The National FINRISK Study National 40-69 40-69 1,248 1,397 1,248 1,397 1,248 1,397 Enzymatic
Homogeneous assay (PEG-
coupled enzymes)
Serum Yes (CDC/CRMLN)
102 Finland 2012 The National FINRISK Study National 40-69 40-69 1,086 1,231 1,086 1,230 1,086 1,230 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (CDC/CRMLN)
103 Finland 2011-2012 Health 2011 Survey National 40-79 40-79 884 1,099 883 1,099 883 1,099 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (CDC/CRMLN)
104 France 1985-1987 MONICA, Strasbourg Subnational 40-59 40-59 446 431 444 430 444 430 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method/Updated 
phosphotungstate-Magnesium 
method after the Boehringer-Ms 
(PTA 543004); Enzymatic
Plasma Yes (WHO-LRC)
105 France 1985-1987 MONICA, Toulouse Subnational 40-59 40-59 422 394 417 391 417 391 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Plasma Yes (WHO-LRC)
106 France 1986-1989 MONICA, Lille Community 40-59 40-59 353 252 350 250 350 250 Enzymatic
Updated phosphotungstate-
Magnesium method after the 
Boehringer-Ms (PTA 543004); 
Enzymatic
Plasma Yes (WHO-LRC)
107 France 1988-1991 MONICA, Toulouse Subnational 40-59 40-59 394 394 394 Enzymatic
Updated phosphotungstate-
Magnesium method after the 
Boehringer-Ms (PTA 543004); 
Enzymatic
Plasma Yes (WHO-LRC)
108 France 1994-1996 MONICA, Toulouse Subnational 40-59 40-59 412 391 412 391 412 391 Enzymatic
Updated phosphotungstate-
Magnesium method after the 
Boehringer-Ms (PTA 543004); 
Enzymatic
Serum Yes (WHO-LRC)
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109 France 1995-1996
Multinational mONItoring of trends and 
determinants of CArdiovascular disease 
in Lille (MONICA Lille)
Community 40-59 40-59 388 412 385 411 385 411 Enzymatic
Updated phosphotungstate-
Magnesium method after the 
Boehringer-Ms (PTA 543004); 
Enzymatic
Serum Yes (WHO-LRC)
110 France 1995-1997 MONICA, Strasbourg Subnational 40-59 40-59 382 356 374 344 374 344 Enzymatic
Updated phosphotungstate-
Magnesium method after the 
Boehringer-Ms (PTA 543004); 
Enzymatic
Serum Yes (WHO-LRC)
111 France 2004-2006
National Monitoring of Arterial Risk in 
Lille (MONA LISA Lille)
Community 40-69 40-69 413 416 413 416 413 416 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (other)
112 France 2005-2007
National Monitoring of Arterial Risk in 
Bas-Rhin (MONA LISA Bas-Rhin)
Subnational 40-69 40-69 407 396 407 396 407 396 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (other)
113 France 2005-2007
Monitoring National du Risque Artériel 
(MONA LISA study Haute-Garonne)
Subnational 40-69 40-69 465 426 465 426 465 426 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (other)
114 France 2006-2007 Etude Nationale Nutrition Santé National 40-69 40-69 363 658 359 649 359 649 Enzymatic
Homogeneous assay (Antibody, 
two reagents)
Serum No
115 France 2011-2013
Enquête LIttorale Souffle Air Biologie 
EnvironnemenT (ELISABET) 
Dunkerque
Community 40-59 40-59 573 612 573 612 573 612 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (other)
116 France 2011-2013
Enquête LIttorale Souffle Air Biologie 
EnvironnemenT (ELISABET) Lille
Community 40-59 40-59 581 681 581 682 581 681 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (other)
117 Germany 1982 MONICA, Erfurt Community 40-59 40-59 48 47 Direct Serum Yes (WHO-LRC)
118 Germany 1982-1984 MONICA, Chemnitz Community 40-59 40-59 136 168 132 162 132 161 Direct PEG 6000 method; Direct Serum Yes (WHO-LRC)
119 Germany 1982-1984 MONICA, Zwickau Community 40-59 40-59 131 128 128 133 126 127 Direct PEG 6000 method; Direct Serum Yes (WHO-LRC)
120 Germany 1984
German Cardiovascular Prevention 
Study (GCP) - National Health Survey 
1984
Subnational 40-69 40-69 1,568 1,484 1,445 1,359 1,443 1,357 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
121 Germany 1984-1985 MONICA, Berlin-Lichtenberg Community 40-59 40-59 405 379 393 372 393 370 Direct
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
122 Germany 1984 MONICA, Bremen North/West Community 40-59 40-59 453 454 412 405 405 400 Enzymatic
Updated phosphotungstate-
Magnesium method after the 
Boehringer-Ms (PTA 543004); 
Enzymatic
Serum Yes (WHO-LRC)
123 Germany 1983-1984 MONICA, Halle County Subnational 40-59 40-59 584 576 535 528 528 520 Direct
Phosphotungstate-Magnesium 
(PTA) method; Direct
Serum Yes (WHO-LRC)
124 Germany 1982-1985
MONICA, Rest of Karl-Marx-Stadt 
County
Subnational 40-59 40-59 292 334 Direct Serum Yes (WHO-LRC)
125 Germany 1982-1985 MONICA, Rest of DDR-MONICA Subnational 40-59 40-59 125 143 59 67 59 67 Direct
Phosphotungstate-Magnesium 
(PTA) method; Direct
Serum Yes (WHO-LRC)
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126 Germany 1984-1985 MONICA, Augsburg Community 40-59 40-59 1,035 977 1,034 1,015 985 965 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
127 Germany 1984-1986 MONICA, Cottbus County Community 40-59 40-59 331 374 326 371 326 371 Direct
Phosphotungstate-Magnesium 
(PTA) method; Direct
Serum Yes (WHO-LRC)
128 Germany 1987-1988 MONICA, Erfurt Community 40-59 40-59 445 434 444 433 444 433 Direct
Phosphotungstate-Magnesium 
(PTA) method; Direct
Serum Yes (WHO-LRC)
129 Germany 1988
German Cardiovascular Prevention 
Study (GCP) - National Health Survey 
1988
Subnational 40-69 40-69 1,613 1,643 1,590 1,633 1,590 1,631 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
130 Germany 1988 MONICA, Berlin-Lichtenberg Community 40-59 40-59 393 389 393 389 393 389 Direct
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
131 Germany 1988 MONICA, Bremen North/West Community 40-69 40-69 388 416 364 381 364 381 Direct/Enzymatic
Updated phosphotungstate-
Magnesium method after the 
Boehringer-Ms (PTA 543004); 
Enzymatic
Serum Yes (WHO-LRC)
132 Germany 1988 MONICA, Bremen Center/South/East Community 40-69 40-69 317 366 309 356 309 356 Direct/Enzymatic
Updated phosphotungstate-
Magnesium method after the 
Boehringer-Ms (PTA 543004); 
Enzymatic
Serum Yes (WHO-LRC)
133 Germany 1988 MONICA, Chemnitz Community 40-59 40-59 141 202 142 202 141 201 Direct PEG 6000 method; Direct Serum Yes (WHO-LRC)
134 Germany 1988 MONICA, Zwickau Community 40-59 40-59 97 120 96 117 96 116 Direct PEG 6000 method; Direct Serum Yes (WHO-LRC)
135 Germany 1989-1990 MONICA, Cottbus County Community 40-59 40-59 258 241 256 236 256 236 Direct
Phosphotungstate-Magnesium 
(PTA) method; Direct
Serum Yes (WHO-LRC)
136 Germany 1988-1989 MONICA, Halle County Subnational 40-59 40-59 488 576 481 573 481 571 Direct PEG 6000 method; Direct Serum Yes (WHO-LRC)
137 Germany 1988-1989
MONICA, Rest of Karl-Marx-Stadt 
County
Subnational 40-59 40-59 258 282 257 283 257 282 Direct PEG 6000 method; Direct Serum Yes (WHO-LRC)
138 Germany 1989-1990 MONICA, Augsburg Community 40-59 40-59 1,014 996 1,003 991 1,003 991 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
139 Germany 1991-1992 MONICA, Bremen North/West Community 40-69 40-69 352 390 325 360 325 359 Enzymatic
Updated phosphotungstate-
Magnesium method after the 
Boehringer-Ms (PTA 543004); 
Enzymatic
Serum Yes (WHO-LRC)
140 Germany 1991-1992 MONICA, Bremen Center/South/East Community 40-69 40-69 330 324 321 314 321 314 Enzymatic
Updated phosphotungstate-
Magnesium method after the 
Boehringer-Ms (PTA 543004); 
Enzymatic
Serum Yes (WHO-LRC)
141 Germany 1991-1992
German Cardiovascular Prevention 
Study (GCP) - National Health Survey 
1991
Subnational 40-69 40-69 1,590 1,628 1,516 1,559 1,515 1,558 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
142 Germany 1991-1992
First National Examination of life 
conditions, Environment and Health in 
East Germany 1991/92
Subnational 40-69 40-69 651 684 591 626 591 625 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
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143 Germany 1991-1992 MONICA, Erfurt Community 40-59 40-59 284 285 284 284 284 284 Unknown
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
144 Germany 1993-1994 MONICA, Chemnitz Community 40-59 40-59 223 256 223 256 223 256 Enzymatic
Updated phosphotungstate-
Magnesium method after the 
Boehringer-Ms (PTA 543004); 
Enzymatic
Serum Yes (WHO-LRC)
145 Germany 1993-1994 MONICA, Zwickau Community 40-59 40-59 60 64 60 64 60 64 Enzymatic
Updated phosphotungstate-
Magnesium method after the 
Boehringer-Ms (PTA 543004); 
Enzymatic
Serum Yes (WHO-LRC)
146 Germany 1994-1995 MONICA, Augsburg Community 40-59 40-59 955 1,036 951 1,036 951 1,036 Enzymatic
Updated phosphotungstate-
Magnesium method after the 
Boehringer-Ms (PTA 543004); 
Enzymatic
Serum Yes (WHO-LRC)
147 Germany 1997-1999
German National Health Interview and 
Examination Survey (GNHIES98) 
National 40-79 40-79 1,940 2,122 1,937 2,122 1,937 2,122 Enzymatic
Homogeneous assay (Antibody, 
two reagents)
Serum Yes (other)
148 Germany 1997-2001
Study of Health in Pomerania (SHIP-0)  
baseline study
Subnational 40-79 40-79 1,461 1,446 1,456 1,441 1,455 1,441 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (other)
149 Germany 1999-2001
KORA S4 Study: Kooperative Research 
in the Region of Augsburg Survey 4
Community 40-69 40-69 1,260 1,316 1,257 1,314 1,257 1,314 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Unknown
150 Germany 2000-2002
Epidemiological study of the chances of 
prevention, early recognition and optimal
treatment of chronic diseases in an 
elderly population (ESTHER)
Subnational 50-69 50-69 3,661 4,442 2,351 2,730 2,334 2,708 Enzymatic Unknown; Enzymatic Serum Unknown
151 Germany 2002
Echinoccoccus Multilocularis and 
Internal Diseases in Leutkirch 
Community 40-59 40-59 378 439 378 439 378 439 Enzymatic
Heparin-Manganese method; 
Enzymatic
Serum Yes (CDC/CRMLN)
152 Germany 2002-2006
Study of Health in Pomerania (SHIP-1) 5
year follow-up 
Subnational 40-79 40-79 1,183 1,261 Enzymatic Electrophoresis Serum Yes (other) 2
153 Germany 2006-2008
KORA F4 Study: Kooperative Research 
in the Region of Augsburg Follow-up of 
Survey 4
Community 40-79 40-79 1,273 1,346 1,273 1,346 1,273 1,346 Enzymatic Homogeneous assay (Catalase) Serum Unknown
154 Germany 2008-2011
Epidemiological study of the chances of 
prevention, early recognition and optimal
treatment of chronic diseases in an 
elderly population (ESTHER)
Subnational 60-79 60-79 1,870 2,198 1,870 2,197 1,870 2,197 Enzymatic Unknown Serum Unknown
155 Germany 2008-2011
German Health Interview and 
Examination Survey for adults 2008-11 
(DEGS1)
National 40-79 40-79 2,453 2,699 2,456 2,699 2,453 2,698 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (other)
156 Germany 2008-2012
Study of Health in Pomerania, second 
cohort (SHIP-TREND)
Subnational 40-79 40-79 1,601 1,657 1,600 1,656 1,600 1,656 Enzymatic Homogeneous assay Serum Yes (other)
157 Iceland 1970-1971 The Reykjavik Study (Men) Subnational 40-59 3,295 Enzymatic Serum Yes (other)
158 Iceland 1971-1972 The Reykjavik Study (Women) Subnational 40-59 3,421 Enzymatic Serum Yes (other)
159 Iceland 1974-1976 The Reykjavik Study (Men) Subnational 40-69 4,525 Enzymatic Serum Yes (other)
160 Iceland 1977-1979 The Reykjavik Study (Women) Subnational 50-69 1,983 Enzymatic Serum Yes (other)
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161 Iceland 1979-1981 The Reykjavik Study (Men) Subnational 50-69 1,595 Enzymatic Serum Yes (other)
162 Iceland 1983 MONICA, Arnes County Community 40-59 40-59 196 231 194 231 194 231 Extraction
Heparin-Manganese method; 
Extraction
Serum Yes (WHO-LRC)
163 Iceland 1983 MONICA, Reykjavik Subnational 40-59 40-59 226 241 224 241 224 241 Extraction
Heparin-Manganese method; 
Extraction
Serum Yes (WHO-LRC)
164 Iceland 1981-1984 The Reykjavik Study (Women) Subnational 50-69 1,685 Enzymatic Serum Yes (other)
165 Iceland 1988-1989 MONICA, Arnes County Community 40-59 40-59 210 221 209 220 209 220 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
166 Iceland 1988-1989 MONICA, Reykjavik Subnational 40-59 40-59 222 232 222 232 222 232 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
167 Iceland 1993-1994 MONICA, Arnes County Community 40-59 40-59 229 259 228 259 228 259 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
168 Iceland 1993-1994 MONICA, Reykjavik Subnational 40-59 40-59 235 223 235 223 235 223 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
169 Iceland 2001-2003 The Reykjavik Study for the young Subnational 50-59 50-59 469 495 469 495 469 495 Enzymatic
Homogeneous assay (Dextran 
sulphate-Magnesium + PEG-
coupled enzymes)
Serum Yes (other)
170 Iceland 2005-2011
Risk Evaluation For INfarct Estimates 
(REFINE)
Subnational 40-69 40-69 1,831 1,928 1,830 1,927 1,830 1,927 Enzymatic
Homogeneous assay (Dextran 
sulphate-Magnesium + PEG-
coupled enzymes)
Serum Yes (other)
171 Iceland 2010-2012
Risk Evaluation For INfarct Estimates 
(REFINE) follow-up visit (REFINELO)
Subnational 40-69 40-69 318 328 318 328 318 328 Enzymatic
Homogeneous assay (Dextran 
sulphate-Magnesium + PEG-
coupled enzymes)
Serum Yes (other)
172 Italy 1982-1987 MONICA, Latina Community 40-59 40-59 445 455 445 453 445 453 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
173 Italy 1985
Finland, Italy, Netherlands, Elderly (Fine
Italy)
Community 70-79 421 420 420 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
174 Italy 1986 MONICA, Friuli Subnational 40-59 40-59 488 471 487 464 487 463 Enzymatic PEG 6000 method; Enzymatic Serum Yes (WHO-LRC)
175 Italy 1986-1987 MONICA-Brianza survey Subnational 40-59 40-59 430 444 430 445 429 444 Enzymatic
Updated phosphotungstate-
Magnesium method after the 
Boehringer-Ms (PTA 543004); 
Enzymatic
Serum Yes (WHO-LRC)
176 Italy 1989 MONICA, Friuli Subnational 40-59 40-59 491 481 491 480 489 479 Enzymatic PEG 6000 method; Enzymatic Serum Yes (WHO-LRC)
177 Italy 1989 Ventimiglia Heart Study Community 40-79 40-79 308 378 308 378 308 378 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Plasma Yes (WHO-LRC)
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178 Italy 1990 Bruneck Study Community 40-79 40-79 469 450 469 450 469 450 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum No
179 Italy 1983-1996
Malattie cardiovascolari 
ATerosclerotiche Istituto Superiore di 
Sanità
Community 40-69 40-69 2,479 2,828 2,476 2,826 2,475 2,826 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
180 Italy 1989-1990 MONICA-Brianza survey Subnational 40-59 40-59 421 429 423 429 421 429 Enzymatic
Updated phosphotungstate-
Magnesium method after the 
Boehringer-Ms (PTA 543004); 
Enzymatic
Serum Yes (WHO-LRC)
181 Italy 1992-1993 Italian Longitudinal Study on Aging National 70-79 70-79 861 771 863 762 852 758 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum No
182 Italy 1994 MONICA, Friuli Subnational 40-59 40-59 486 509 485 508 485 507 Enzymatic PEG 6000 method; Enzymatic Serum Yes (WHO-LRC)
183 Italy 1993-1994 MONICA-Brianza survey Subnational 40-59 40-59 423 459 423 459 422 459 Enzymatic
Updated phosphotungstate-
Magnesium method after the 
Boehringer-Ms (PTA 543004); 
Enzymatic
Serum Yes (WHO-LRC)
184 Italy 1995 Bruneck Study Community 50-79 50-79 313 322 313 322 313 322 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum No
185 Italy 1995-1996 Italian Longitudinal Study on Aging National 70-79 70-79 591 506 582 496 580 496 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum No
186 Italy 1995-1999 PROgetto Veneto Anziani (PROVA) Subnational 70-79 70-79 485 738 481 735 481 735 Enzymatic
Dextran sulphate-Magnesium 
method; Enzymatic
Serum Yes (other)
187 Italy 1998-1999 progetto VIP Community 40-69 40-69 358 353 340 335 340 334 Enzymatic
Homogeneous assay (Antibody, 
two reagents)
Serum Yes (other)
188 Italy 2000 Bruneck Study Community 50-79 50-79 295 309 295 309 295 309 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum No
189 Italy 1998-2002
Osservatorio Epidemiologico 
Cardiovascolare
National 40-69 40-69 3,738 3,624 3,743 3,630 3,737 3,624 Enzymatic
Updated phosphotungstate-
Magnesium method after the 
Boehringer-Ms (PTA 543004); 
Enzymatic
Serum Yes (CDC/CRMLN)
190 Italy 2001-2003 The Study of Asti Community 50-59 50-59 411 453 411 453 411 453 Enzymatic
Heparin-Manganese method; 
Enzymatic
Plasma No
191 Italy 2000-2003 PROgetto Veneto Anziani (PROVA) Subnational 70-79 70-79 440 749 361 621 361 620 Enzymatic
Dextran sulphate-Magnesium 
method; Enzymatic
Serum Yes (other)
192 Italy 2003 The European Male Ageing Study Community 40-79 431 431 431 Unknown Unknown Unknown Unknown
193 Italy 2002-2005 PROgetto Veneto Anziani (PROVA) Subnational 70-79 70-79 307 542 308 540 307 540 Enzymatic
Dextran sulphate-Magnesium 
method; Enzymatic
Serum Yes (other)
194 Italy 2005 Bruneck Study Community 60-79 60-79 181 187 181 187 181 187 Enzymatic
Homogeneous assay (Dextran 
sulphate-Magnesium + PEG-
coupled enzymes)
Serum No
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195 Italy 2004-2005
Italian Project on the Epidemiology of 
Alzheimer's Disease
National 70-79 70-79 709 623 Unknown Unknown Unknown
196 Italy 2004-2005 Vobarno study Community 60-69 60-69 53 63 53 62 53 62 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (other)
197 Italy 2008 The European Male Ageing Study Community 40-79 262 263 262 Unknown Unknown Unknown Unknown
198 Italy 2005-2010 Moli-sani Study Subnational 40-79 40-79 10,459 11,199 10,458 11,200 10,456 11,198 Enzymatic
Homogeneous assay (Immuno-
enzymatic)
Serum Yes (CDC/CRMLN)
199 Italy 2008-2009 progetto VIP Community 40-69 40-69 356 372 356 370 354 370 Enzymatic
Homogeneous assay (Antibody, 
two reagents)
Serum Yes (other)
200 Italy 2010 Bruneck Study Community 60-79 60-79 181 185 181 185 181 185 Enzymatic
Homogeneous assay (Dextran 
sulphate-Magnesium + PEG-
coupled enzymes)
Serum No
201 Italy 2009-2010
Grosso et al., J Epidemiol. 2014; 24: 327-
33
Community 40-79 40-79 498 822 498 822 498 822 Enzymatic
Heparin-Manganese method; 
Enzymatic
Plasma No
202 Italy 2008-2012
Osservatorio Epidemiologico 
Cardiovascolare/Health Examination 
Survey
National 40-79 40-79 3,927 3,912 3,928 3,911 3,926 3,911 Enzymatic
Homogeneous assay (Immuno-
enzymatic)
Serum Yes (CDC/CRMLN)
203 Italy 2010-2012
CArdiovascular risk MEtabolic 
syndrome LIver and Autoimmunity 
diseases (CA.ME.LI.A)
Community 40-69 40-69 291 303 290 304 290 303 Enzymatic
Homogeneous assay (Dextran 
sulphate-Magnesium + PEG-
coupled enzymes)
Serum No
204 Italy 2011-2012 Vobarno study Community 50-59 50-59 87 111 86 111 86 111 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (other)
205 Italy 2015 Bruneck Study Community 70-79 70-79 84 79 84 79 84 79 Enzymatic
Homogeneous assay (Dextran 
sulphate-Magnesium + PEG-
coupled enzymes)
Serum No
206 Japan 1980 APCSC-Hisayama   Community 40-79 40-79 3,494 2,435 Unknown Unknown Unknown
207 Japan 1980 National Cardiovascular Survey National 40-79 40-79 3,376 4,233 Direct Serum Yes (CDC/CRMLN)
208 Japan 1981 APCSC-Hisayama   Community 40-69 40-69 820 1,074 Unknown Unknown Unknown
209 Japan 1980-1983 Aito Town Study Community 40-69 40-69 672 848 442 449 442 449 Unknown Unknown Serum Unknown
210 Japan 1985-1986 Akabane Study Community 40-69 40-69 812 1,022 812 1,022 812 1,022 Unknown Unknown Serum Unknown
211 Japan 1987 Konan Town Study Community 40-79 40-79 46 62 46 62 46 62 Unknown Unknown Serum Unknown
212 Japan 1988 Konan Town Study Community 40-79 40-79 54 62 54 62 54 62 Unknown Unknown Serum Unknown
213 Japan 1989 Konan Town Study Community 40-79 40-79 42 43 42 43 42 43 Unknown Unknown Serum Unknown
214 Japan 1988-1990 Miyama Cohort Study Community 40-79 40-79 155 256 151 255 151 255 Unknown Unknown Serum Unknown
215 Japan 1989 National Nutrition Survey National 40-79 40-79 2,125 3,044 2,124 3,043 2,123 3,043 Enzymatic
Heparin-Calcium method; 
Unknown
Serum Yes (CDC/CRMLN)
216 Japan 1990
Serum Lipid Survey; Yamamoto et al., J 
Atheroscler Thromb 2003; 10: 176-85
National 40-79 40-79 14,291 9,971 Enzymatic Serum Yes (CDC/CRMLN)
217 Japan 1990 Konan Town Study Community 40-79 40-79 20 36 20 36 20 36 Unknown Unknown Serum Unknown
218 Japan 1990
National Nutrition Survey and National 
Cardiovascular Survey
National 40-79 40-79 2,594 3,477 2,592 3,477 2,592 3,477 Enzymatic
Heparin-Calcium method; 
Unknown
Serum Yes (CDC/CRMLN)
219 Japan 1991 Konan Town Study Community 40-79 40-79 77 97 77 97 77 97 Unknown Unknown Serum Unknown
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220 Japan 1991 Shigaraki Town Study Community 40-79 40-79 203 277 203 277 203 277 Unknown Unknown Serum Unknown
221 Japan 1991 National Nutrition Survey National 40-79 40-79 2,349 3,250 2,348 3,249 2,348 3,249 Enzymatic
Heparin-Calcium method; 
Unknown
Serum Yes (CDC/CRMLN)
222 Japan 1992 Konan Town Study Community 40-79 40-79 34 41 34 41 34 41 Unknown Unknown Serum Unknown
223 Japan 1992 Shigaraki Town Study Community 40-79 40-79 233 324 233 324 233 324 Unknown Unknown Serum Unknown
224 Japan 1990-1994
Japan Public Health Center-based 
prospective Study (JPHC Study), Cohort 
I
Subnational 40-59 40-59 8,762 14,504 2,856 3,708 2,851 3,702 Enzymatic Unknown Serum Yes (CDC/CRMLN)
225 Japan 1992 National Nutrition Survey National 40-79 40-79 2,257 3,126 2,257 3,126 2,257 3,126 Enzymatic
Heparin-Calcium method; 
Unknown
Serum Yes (CDC/CRMLN)
226 Japan 1993 Konan Town Study Community 40-79 40-79 39 49 39 49 39 49 Unknown Unknown Serum Unknown
227 Japan 1993 Shigaraki Town Study Community 40-79 40-79 260 373 260 373 260 373 Unknown Unknown Serum Unknown
228 Japan 1993 National Nutrition Survey National 40-79 40-79 2,007 2,890 2,007 2,890 2,007 2,890 Enzymatic
Heparin-Calcium method; 
Unknown
Serum Yes (CDC/CRMLN)
229 Japan 1994 Konan Town Study Community 40-79 40-79 28 43 28 43 28 43 Unknown Unknown Serum Unknown
230 Japan 1994 Shigaraki Town Study Community 40-79 40-79 206 269 206 269 206 269 Unknown Unknown Serum Unknown
231 Japan 1993-1994
Japan Public Health Center-based 
prospective Study (JPHC Study), Cohort 
II
Subnational 40-69 40-69 8,557 16,214 8,549 16,207 8,549 16,206 Enzymatic Unknown Serum Yes (CDC/CRMLN)
232 Japan 1994 National Nutrition Survey National 40-59 40-59 1,067 1,675 1,067 1,675 1,067 1,675 Enzymatic
Heparin-Calcium method; 
Unknown
Serum Yes (CDC/CRMLN)
233 Japan 1995 Konan Town Study Community 40-79 40-79 37 51 37 51 37 51 Unknown Unknown Serum Unknown
234 Japan 1995 Shigaraki Town Study Community 40-79 40-79 237 380 237 380 237 380 Unknown Unknown Serum Unknown
235 Japan 1995 National Nutrition Survey National 40-59 40-59 985 1,618 985 1,618 985 1,618 Enzymatic
Heparin-Calcium method; 
Unknown
Serum Yes (CDC/CRMLN)
236 Japan 1996 Shigaraki Town Study Community 40-79 40-79 70 115 70 115 70 115 Unknown Unknown Serum Unknown
237 Japan 1996 National Nutrition Survey National 40-79 40-79 1,799 2,731 1,799 2,730 1,799 2,730 Enzymatic
Homogeneous assay (selective 
inhibition)
Serum Yes (CDC/CRMLN)
238 Japan 1997 Shigaraki Town Study Community 40-79 40-79 45 73 45 73 45 73 Unknown Unknown Serum Unknown
239 Japan 1997 National Nutrition Survey National 40-79 40-79 1,845 2,685 1,844 2,685 1,844 2,685 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (CDC/CRMLN)
240 Japan 1998 National Nutrition Survey National 40-79 40-79 1,900 2,740 1,899 2,740 1,899 2,740 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (CDC/CRMLN)
241 Japan 1999 National Nutrition Survey National 40-79 40-79 1,547 2,268 1,546 2,268 1,546 2,268 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (CDC/CRMLN)
242 Japan 2000
National Nutrition Survey and National 
Cardiovascular Survey
National 40-79 40-79 1,714 2,402 1,714 2,402 1,713 2,402 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (CDC/CRMLN)
243 Japan 2001
The Japan Association of Health Service 
Database
Subnational 40-79 40-79 804,504 764,081 804,504 764,081 804,504 764,081 Unknown Unknown Serum Yes (other)
244 Japan 2001 National Nutrition Survey National 40-79 40-79 1,647 2,436 1,646 2,436 1,646 2,436 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (CDC/CRMLN)
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245 Japan 2002 National Nutrition Survey National 40-79 40-79 1,635 2,320 1,634 2,320 1,634 2,320 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (CDC/CRMLN)
246 Japan 2002-2003 The Hisayama Study Community 40-79 40-79 1,312 1,672 1,312 1,672 1,312 1,672 Enzymatic Unknown Serum No
247 Japan 2003 National Health and Nutrition Survey National 40-79 40-79 1,567 2,307 1,566 2,306 1,566 2,306 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (CDC/CRMLN)
248 Japan 2004 National Health and Nutrition Survey National 40-79 40-79 1,173 1,736 1,172 1,736 1,172 1,736 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (CDC/CRMLN)
249 Japan 2005 National Health and Nutrition Survey National 40-79 40-79 1,195 1,719 1,195 1,719 1,195 1,719 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (CDC/CRMLN)
250 Japan 2006 National Health and Nutrition Survey National 40-79 40-79 1,316 1,858 1,316 1,858 1,316 1,858 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (CDC/CRMLN)
251 Japan 2007 National Health and Nutrition Survey National 40-79 40-79 1,228 1,730 1,228 1,730 1,228 1,730 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (CDC/CRMLN)
252 Japan 2008 National Health and Nutrition Survey National 40-79 40-79 1,388 1,956 1,387 1,956 1,387 1,956 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (CDC/CRMLN)
253 Japan 2009 National Health and Nutrition Survey National 40-79 40-79 1,328 1,881 1,327 1,881 1,327 1,881
Cholesterol 
dehydrogenase-
ultraviolet method
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (CDC/CRMLN)
254 Japan 2010 National Health and Nutrition Survey National 40-79 40-79 1,229 1,681 1,229 1,681 1,229 1,681
Cholesterol 
dehydrogenase-
ultraviolet method
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (CDC/CRMLN)
255 Japan 2011 National Health and Nutrition Survey National 40-79 40-79 1,070 1,515 1,070 1,515 1,070 1,515
Cholesterol 
dehydrogenase-
ultraviolet method
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (CDC/CRMLN)
256 Japan 2011
The Tokyo Health Service Association 
Database
Community 40-79 40-79 22,650 8,013 40,651 20,574 22,650 8,013 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (other)
257 Japan 2012 National Health and Nutrition Survey National 40-79 40-79 4,373 6,262 4,373 6,262 4,373 6,262
Cholesterol 
dehydrogenase-
ultraviolet method
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (CDC/CRMLN)
258 Japan 2013 National Health and Nutrition Survey National 40-79 40-79 1,065 1,455 1,065 1,455 1,065 1,455
Cholesterol 
dehydrogenase-
ultraviolet method
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (CDC/CRMLN)
259 Japan 2014 National Health and Nutrition Survey National 40-79 40-79 1,169 1,553 1,169 1,553 1,169 1,553
Cholesterol 
dehydrogenase-
ultraviolet method
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (CDC/CRMLN)
260 Japan 2015 National Health and Nutrition Survey National 40-79 40-79 1,030 1,523 1,030 1,523 1,030 1,523
Cholesterol 
dehydrogenase-
ultraviolet method
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (CDC/CRMLN)
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261 Japan 2016 National Health and Nutrition Survey National 40-79 40-79 3,571 5,092 3,571 5,092 3,571 5,092
Cholesterol 
dehydrogenase-
ultraviolet method
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (CDC/CRMLN)
262 Lithuania 1972-1974
Kaunas Rotterdam Intervention Study 
(KRIS)
Community 50-59 1,382 Enzymatic Serum Yes (other)
263 Lithuania 1977-1980
Multifactorial Prevention of Ischaemic 
Heart Disease, Kaunas
Community 40-59 5,633 Enzymatic Serum Yes (other)
264 Lithuania 1983-1985 MONICA, Kaunas Community 40-59 40-59 504 518 464 448 463 448 Enzymatic
Heparin-Manganese method; 
Enzymatic
Serum Yes (WHO-LRC)
265 Lithuania 1987
Countrywide Integrated 
Noncommunicable Diseases Intervention 
Programme survey
Subnational 40-59 40-59 563 587 522 557 521 557 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
266 Lithuania 1986-1987 MONICA, Kaunas Community 40-59 40-59 620 587 595 564 595 564 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
267 Lithuania 1992-1993 MONICA, Kaunas Community 40-59 40-59 398 427 383 406 382 405 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
268 Lithuania 1992-1993
Countrywide Integrated 
Noncommunicable Diseases Intervention 
Programme survey
Subnational 40-59 40-59 348 487 298 422 297 422 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
269 Lithuania 1998-1999
Countrywide Integrated 
Noncommunicable Diseases Intervention 
Programme survey
Subnational 40-59 40-59 446 560 439 543 439 543 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
270 Lithuania 2001-2002 MONICA4 Community 40-59 40-59 436 572 420 530 420 530 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
271 Lithuania 2006-2007
Countrywide Integrated 
Noncommunicable Diseases Intervention 
Programme survey
Subnational 40-59 40-59 438 555 438 556 438 555 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (other)
272 Lithuania 2006-2008 MONICA4 Follow-up Community 50-69 50-69 118 172 118 169 118 169 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
273 New Zealand 1982 MONICA, Auckland Community 40-59 40-59 737 392 629 363 629 362 Extraction
Phosphotungstate-Magnesium 
(PTA) method; Extraction
Serum Yes (WHO-LRC)
274 New Zealand 1989 The Life in New Zealand Survey National 40-79 40-79 527 570 Enzymatic Serum Yes (CDC/CRMLN)
275 New Zealand 1993-1994 MONICA, Auckland Community 40-59 40-59 512 472 509 468 509 468 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
276 New Zealand 1996-1997 National Nutrition Survey National 40-79 40-79 505 525 504 525 504 525 Enzymatic
Homogeneous assay (alpha-
Cyclodextrin + PEG-coupled 
enzymes)
Serum Yes (CDC/CRMLN)
277 New Zealand 2002-2003 Diabetes, Heart and Health Survey Subnational 40-79 40-79 977 1,112 974 1,112 974 1,112 Enzymatic
Homogeneous assay (alpha-
Cyclodextrin + PEG-coupled 
enzymes)
Serum Yes (other)
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278 New Zealand 2008-2009
2008/09 New Zealand Adult Nutrition 
Survey
National 40-79 40-79 332 442 332 442 332 442 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (CDC/CRMLN)
279 Norway 1979-1980 The Tromsø Study: Tromsø 2 Community 40-49 40-49 1,908 1,854 1,900 1,852 1,900 1,852 Enzymatic
Heparin-Manganese method; 
Enzymatic
Serum Unknown
280 Norway 1986-1987 The Tromsø Study: Tromsø 3 Community 40-59 40-49 4,272 2,564 4,269 2,564 4,266 2,562 Enzymatic
Heparin-Manganese method; 
Enzymatic
Serum Yes (WHO-LRC)
281 Norway 1994-1995 The Tromsø Study: Tromsø 4 Community 40-79 40-79 5,481 5,550 5,467 5,544 5,464 5,542 Enzymatic
Heparin-Manganese method; 
Enzymatic
Serum Unknown
282 Norway 1995-1997 HUNT2 study Subnational 40-79 40-79 11,821 12,744 11,810 12,742 11,810 12,742 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (other)
283 Norway 2001-2002
The Tromsø Study: Tromsø 5, Tromsø 
Study Panel
Community 40-79 40-79 441 871 441 870 441 870 Enzymatic
Homogeneous assay (Dextran 
sulphate-Magnesium + PEG-
coupled enzymes)
Serum Yes (CDC/CRMLN)
284 Norway 2006-2008 HUNT3 Study Subnational 40-79 40-79 9,726 11,146 9,726 11,146 9,726 11,146 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (other)
285 Norway 2007-2008 The Tromsø Study: Tromsø 6 Community 40-79 40-79 2,785 3,141 2,784 3,139 2,784 3,139 Enzymatic
Homogeneous assay (Dextran 
sulphate-Magnesium + PEG-
coupled enzymes)
Serum Yes (CDC/CRMLN)
286 Poland 1983-1984 MONICA, Tarnobrzeg Voivodship Community 40-59 40-59 835 975 835 975 835 975 Direct
Heparin-Manganese method; 
Direct
Plasma Yes (WHO-LRC)
287 Poland 1983-1985 MONICA, Warsaw Community 40-59 40-59 891 901 887 897 886 897 Direct
Heparin-Manganese method; 
Direct
Plasma Yes (WHO-LRC)
288 Poland 1987-1988 MONICA, Tarnobrzeg Voivodship Community 40-59 40-59 419 440 419 440 419 440 Direct
Heparin-Manganese method; 
Direct
Plasma Yes (WHO-LRC)
289 Poland 1988-1989 MONICA, Warsaw Community 40-59 40-59 475 492 467 490 467 490 Direct
Heparin-Manganese method; 
Direct
Plasma Yes (WHO-LRC)
290 Poland 1989-1990
Polish Program CINDI (CINDI Lodz 
1989-1990)
Community 40-59 40-59 393 468 Enzymatic Serum Yes (other)
291 Poland 1992-1993 MONICA, Tarnobrzeg Voivodship Community 40-59 40-59 414 469 414 469 414 469 Direct
Heparin-Manganese method; 
Enzymatic
Plasma Yes (WHO-LRC)
292 Poland 1993 MONICA, Warsaw Community 40-59 40-59 522 548 518 547 518 547 Enzymatic
Heparin-Manganese method; 
Enzymatic
Plasma Yes (WHO-LRC)
293 Poland 1995-1996
Polish Program CINDI (CINDI Lodz 
1995)
Community 40-59 40-59 365 541 365 540 365 540 Enzymatic Homogeneous assay Serum Yes (other)
294 Poland 1997 NATPOL National 40-79 40-79 241 214 Accutrend Capillary Unknown
295 Poland 2000
The health status, risk factors of chronic 
diseases and health behaviors of 
residents of Torun (CINDI Torun 2000)
Community 40-79 40-79 452 497 451 497 451 497 Enzymatic Homogeneous assay Serum Yes (other)
296 Poland 2001-2002
The health status, risk factors of chronic 
diseases and health behaviors of 
residents of Lodz (CINDI Lodz 2001)
Community 40-59 40-59 485 354 485 353 485 353 Enzymatic Homogeneous assay Serum Yes (other)
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297 Poland 2002 NATPOL National 40-79 40-79 390 490 390 490 390 490 Enzymatic
Homogeneous assay (Dextran 
sulphate-Magnesium + PEG-
coupled enzymes)
Serum Yes (other)
298 Poland 2003 The European Male Ageing Study Community 40-79 196 196 196 Unknown Unknown Unknown Unknown
299 Poland 2004
LIPIDOGRAM2004 Study - National 
epidemiological study of lipid disorders 
and selected risk factors of 
cardiovascular disease in primary health 
care in Poland
National 40-79 40-79 4,138 5,883 4,138 5,883 4,138 5,883 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (CDC/CRMLN)
300 Poland 2003-2005
National Multicenter Health Survey in 
Poland. Project WOBASZ
National 40-69 40-69 2,741 2,992 2,739 2,990 2,739 2,990 Enzymatic
Heparin-Manganese method; 
Enzymatic
Serum Yes (WHO-LRC)
301 Poland 2006
The health, risk factors for chronic 
diseases, attitudes and behaviors of 
health residents of Torun (CINDI Torun 
2006)
Community 40-59 40-59 376 588 376 588 376 588 Enzymatic Homogeneous assay Serum Yes (other)
302 Poland 2006
LIPIDOGRAM2006 Study - National 
epidemiological study of lipid disorders 
and selected risk factors of 
cardiovascular disease in primary health 
care in Poland
National 40-79 40-79 3,688 5,881 3,688 5,880 3,688 5,880 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (CDC/CRMLN)
303 Poland 2008 The European Male Ageing Study Community 40-79 112 112 112 Unknown Unknown Unknown Unknown
304 Poland 2003-2013 Mogielica Human Ecology Study Community 50-79 50-79 11 65 11 65 11 65 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (other)
305 Poland 2011 NATPOL National 40-79 40-79 440 395 439 395 439 395 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (other)
306 Poland 2013-2014
National Multicenter Health Survey in 
Poland. Project WOBASZ II
National 40-79 40-79 1,019 1,298 1,014 1,297 1,014 1,297 Enzymatic
Homogeneous assay (Dextran 
sulphate-Magnesium + PEG-
coupled enzymes)
Serum Yes (CDC/CRMLN)
307 Poland 2015-2016
LIPIDOGRAM2015 & 
LIPIDOGEN2015 Study - National 
epidemiological study of lipid disorders 
and selected risk factors of 
cardiovascular disease in primary health 
care in Poland
National 40-79 40-79 2,099 3,734 2,100 3,733 2,098 3,733 Enzymatic
Homogeneous assay (Immuno-
enzymatic)
Serum Yes (CDC/CRMLN)
308 Slovakia 1993
Countrywide Integrated 
Noncommunicable Diseases Intervention 
Programme
National 40-59 40-59 331 564 314 538 313 538 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (WHO-LRC)
309 Slovakia 1998
Countrywide Integrated 
Noncommunicable Diseases Intervention 
Programme
National 40-59 40-59 415 476 406 475 405 474 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (WHO-LRC)
310 Slovakia 2003
Countrywide Integrated 
Noncommunicable Diseases Intervention 
Programme
National 40-59 40-59 302 467 301 465 301 465 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (WHO-LRC)
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311 Slovakia 2008
Countrywide Integrated 
Noncommunicable Diseases Intervention 
Programme
National 40-59 40-59 195 286 195 286 195 286 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (WHO-LRC)
312 Slovakia 2011-2012 European Health Examination Survey National 40-59 40-59 395 507 395 506 395 506 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (CDC/CRMLN)
313 South Korea 1998
Korea National Health and Nutrition 
Examination Survey
National 40-79 40-79 1,737 2,135 1,737 2,135 1,737 2,135 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum No
314 South Korea 2001
Korea National Health and Nutrition 
Examination Survey
National 40-79 40-79 1,267 1,619 1,271 1,625 1,263 1,608 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum No
315 South Korea 2002-2003 Korean National Health Insurance National 40-79 40-79 2,970,160 2,469,861 Enzymatic Serum Yes (other)
316 South Korea 2005
Korea National Health and Nutrition 
Examination Survey
National 40-79 40-79 1,472 1,896 1,470 1,895 1,470 1,895 Enzymatic Homogeneous assay Serum No
317 South Korea 2004-2005 Korean National Health Insurance National 40-79 40-79 3,572,663 3,239,712 Enzymatic Serum Yes (other)
318 South Korea 2007
Korea National Health and Nutrition 
Examination Survey
National 40-79 40-79 757 1,014 757 1,014 757 1,014 Enzymatic Homogeneous assay Serum No
319 South Korea 2006-2007 Korean National Health Insurance National 40-79 40-79 4,294,406 4,318,878 Enzymatic Serum Yes (other)
320 South Korea 2008
Korea National Health and Nutrition 
Examination Survey
National 40-79 40-79 1,716 2,336 1,715 2,336 1,715 2,336 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (CDC/CRMLN)
321 South Korea 2009
Korea National Health and Nutrition 
Examination Survey
National 40-79 40-79 1,959 2,557 1,958 2,557 1,958 2,557 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (CDC/CRMLN)
322 South Korea 2008-2009 Korean National Health Insurance National 40-79 40-79 5,440,602 5,674,367 Enzymatic Serum Yes (other)
323 South Korea 2010
Korea National Health and Nutrition 
Examination Survey
National 40-79 40-79 1,698 2,117 1,698 2,117 1,698 2,117 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (CDC/CRMLN)
324 South Korea 2011
Korea National Health and Nutrition 
Examination Survey
National 40-79 40-79 1,719 2,203 1,719 2,203 1,719 2,203 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (CDC/CRMLN)
325 South Korea 2010-2011 Korean National Health Insurance National 40-79 40-79 6,582,856 6,990,887 Enzymatic
Unknown (multiple separation 
techniques used); Enzymatic
Serum Yes (other) 3
326 South Korea 2012
Korea National Health and Nutrition 
Examination Survey
National 40-79 40-79 1,635 2,141 1,634 2,140 1,634 2,140 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (CDC/CRMLN)
327 South Korea 2013
Korea National Health and Nutrition 
Examination Survey
National 40-79 40-79 1,515 1,929 1,515 1,929 1,515 1,929 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (CDC/CRMLN)
328 South Korea 2012-2013 Korean National Health Insurance National 40-79 40-79 7,138,521 7,601,045 Enzymatic
Unknown (multiple separation 
techniques used); Enzymatic
Serum Yes (other) 3
329 South Korea 2014
Korea National Health and Nutrition 
Examination Survey
National 40-79 40-79 1,452 1,933 1,452 1,933 1,452 1,933 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (CDC/CRMLN)
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330 South Korea 2015
Korea National Health and Nutrition 
Examination Survey
National 40-79 40-79 1,575 2,011 1,575 2,011 1,575 2,011 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (CDC/CRMLN)
331 South Korea 2014-2015 Korean National Health Insurance National 40-79 40-79 7,707,179 8,108,953 Enzymatic
Unknown (multiple separation 
techniques used); Enzymatic
Serum Yes (other) 3
332 South Korea 2016
Korea National Health and Nutrition 
Examination Survey
National 40-79 40-79 1,674 2,132 1,673 2,132 1,673 2,132 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (CDC/CRMLN)
333 Spain 1986-1988 MONICA, Catalonia Community 40-59 40-59 645 662 645 663 645 662 Enzymatic PEG 6000 method; Enzymatic Serum Yes (WHO-LRC)
334 Spain 1989
Cardiovascular Risk Factors Study in 
Catalonia
Subnational 40-79 40-79 99 90 99 90 99 90 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (CDC/CRMLN)
335 Spain 1990
Hernandez Lanchas et al., An Med 
Interna 1992; 9: 64-71
Community 40-79 40-49 103 17 Unknown Unknown Unknown
336 Spain 1990
Hernandez Lanchas et al., An Med 
Interna 1992; 9: 64-71
Community 40-79 40-69 95 159 Unknown Unknown Unknown
337 Spain 1990-1992 MONICA, Catalonia Community 40-59 40-59 876 491 876 491 876 491 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
338 Spain 1991-1993
Encuesta de Factores de Riesgo 
Cardiovascular en la Región de Murcia 
(Cardiovascular Risk Factors Survey)
Subnational 40-69 40-69 568 639 540 609 540 609 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Unknown
339 Spain 1994-1996 MONICA, Catalonia Community 40-59 40-59 888 775 888 775 888 775 Enzymatic
Updated phosphotungstate-
Magnesium method after the 
Boehringer-Ms (PTA 543004); 
Enzymatic
Serum Yes (WHO-LRC)
340 Spain 1999-2000
Factores de riesgo en las islas Baleares: 
Estudio CORSAIB
Subnational 40-69 40-69 616 693 615 690 615 690 Enzymatic Homogeneous assay (Catalase) Unknown Unknown
341 Spain 2000-2001 EUREYE Study Subnational 70-79 70-79 141 149 Enzymatic Plasma Yes (other)
342 Spain 2001-2002 Catalan Health Interview Survey Subnational 40-69 40-69 339 379 344 380 339 379 Enzymatic Unknown; Enzymatic Serum Unknown
343 Spain 2001-2003
DIabetes, Nutrición y Obesidad en la 
población adulta de la Región de Murcia 
(DINO)
Subnational 40-79 40-79 403 454 403 454 403 454 Enzymatic Homogeneous assay (Catalase) Serum Yes (other)
344 Spain 2000-2005 CDC of the Canary Islands Subnational 40-69 40-69 1,629 2,130 1,628 2,130 1,628 2,130 Enzymatic
Dextran sulphate-Magnesium 
method; Enzymatic
Serum Yes (other)
345 Spain 2003 The European Male Ageing Study Community 40-79 406 402 402 Unknown Unknown Unknown Unknown
346 Spain 2004 Vioque et al., Obesity 2008; 16: 664-670 Community 40-79 40-79 45 58 45 58 45 58 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Unknown
347 Spain 2004
Cardiovascular Risk Study in Castilla y 
León (RECCyL)
Subnational 40-79 40-79 1,175 1,215 1,165 1,194 1,165 1,194 Enzymatic
Homogeneous assay (alpha-
Cyclodextrin + PEG-coupled 
enzymes)
Serum Unknown
348 Spain 2003-2005 Registre Gironi del Cor (REGICOR) Subnational 40-79 40-79 2,686 2,952 2,687 2,952 2,686 2,952 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
22
Male Female Male Female Male Female Male Female Total cholesterol
HDL cholesterol
(separation and quantification 
methods)
Age range as used 
for the analysis
Country Data years Survey/Study name/Citation
Level of 
representati-
veness
Note
Sample size
(Total cholesterol)
Sample size
(HDL cholesterol)
Method used to measure
Whether 
lipids were 
measured in 
serum or 
plasma 
samples
Participating to a 
lipid standardisation 
programme or 
quality control 
schemes
Sample size
(Non-HDL 
cholesterol)
349 Spain 2004-2006 PREVICTUS National 60-79 60-79 2,936 3,256 2,648 2,933 2,645 2,931 Unknown (multiple lab) Unknown Unknown Unknown
350 Spain 2008 The European Male Ageing Study Community 40-79 243 240 240 Unknown Unknown Unknown Unknown
351 Spain 2007-2009
Harmonizing Equation of Risk in 
Mediterraneon countries EXtremadura
Subnational 40-79 40-79 969 1,118 968 1,116 968 1,116 Enzymatic
Homogeneous assay (Dextran 
sulphate-Magnesium + PEG-
coupled enzymes)
Serum Yes (other)
352 Spain 2008-2010
Study on Nutrition and Cardiovascular 
Risk in Spain
National 40-79 40-79 3,894 4,282 3,894 4,282 3,894 4,282 Enzymatic Homogeneous assay (Catalase) Serum Yes (other)
353 Spain 2009
Cardiovascular Risk Study in Castilla y 
León (RECCyL)
Subnational 40-79 40-79 877 1,026 862 1,014 862 1,014 Enzymatic
Homogeneous assay (alpha-
Cyclodextrin + PEG-coupled 
enzymes)
Serum Unknown
354 Spain 2014
Cardiovascular Risk Study in Castilla y 
León (RECCyL)
Subnational 40-79 40-79 857 1,005 830 975 829 974 Enzymatic
Homogeneous assay (alpha-
Cyclodextrin + PEG-coupled 
enzymes)
Serum Unknown
355 Spain 2015
Study on Nutrition and Cardiovascular 
Risk in Spain (ENRICA)
National 70-79 70-79 353 454 353 454 353 454 Enzymatic Homogeneous assay (Catalase) Serum Yes (other)
356 Sweden 1985 MONICA Gothenburg Community 40-59 40-59 336 377 Enzymatic Serum Yes (WHO-LRC)
357 Sweden 1986 MONICA Northern Sweden Subnational 40-59 40-59 417 426 Enzymatic Serum Yes (WHO-LRC)
358 Sweden 1990 MONICA Northern Sweden Subnational 40-59 40-59 397 407 Enzymatic Serum Yes (WHO-LRC)
359 Sweden 1990 MONICA Gothenburg Community 40-59 40-59 391 429 Enzymatic Serum Yes (WHO-LRC)
360 Sweden 1992-1994 Malmö Diet and Cancer Community 50-59 50-59 1,052 1,483 Unknown Unknown Unknown
361 Sweden 1994 MONICA Northern Sweden Subnational 40-69 40-69 393 404 Enzymatic Serum Yes (WHO-LRC)
362 Sweden 1995 MONICA Gothenburg Community 40-59 40-59 390 469 Enzymatic Serum Yes (WHO-LRC)
363 Sweden 1999 MONICA Northern Sweden Subnational 40-69 40-69 341 406 Enzymatic Serum Yes (other)
364 Sweden 2003 The European Male Ageing Study Community 40-79 210 Unknown Unknown Unknown
365 Sweden 2001-2004 Swedish INTERGENE Cohort Study Subnational 40-69 40-69 716 748 Enzymatic Serum No
366 Sweden 2004 MONICA Northern Sweden Subnational 40-69 40-69 372 410 Enzymatic Serum Yes (other)
367 Sweden 2008 The European Male Ageing Study Community 40-79 135 Unknown Unknown Unknown
368 Sweden 2009 MONICA Northern Sweden Subnational 40-69 40-69 358 360 Enzymatic Serum Yes (other)
369 Sweden 2014 MONICA Northern Sweden Subnational 40-69 40-69 305 343 Enzymatic Serum Yes (other)
370 Switzerland 1984-1986 The Swiss MONICA Study Wave I Subnational 40-69 40-69 930 827 929 827 929 827 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum/ 
plasma
Yes (WHO-LRC)
371 Switzerland 1988-1989 The Swiss MONICA Study Wave II Subnational 40-69 40-69 953 874 953 874 953 874 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
372 Switzerland 1992-1993 The Swiss MONICA Study Wave III Subnational 40-69 40-69 871 915 871 915 871 915 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
373 Switzerland 2003-2006 Cohorte Lausannoise (CoLaus) Community 40-69 40-69 1,840 2,007 1,840 2,006 1,840 2,006 Enzymatic
Homogeneous assay (alpha-
Cyclodextrin + PEG-coupled 
enzymes)
Plasma No
374 Switzerland 2007-2012 Bus Santé Study Subnational 40-79 40-79 1,020 1,009 1,020 1,009 1,020 1,009 Enzymatic
Homogeneous assay (Dextran 
sulphate-Magnesium + PEG-
coupled enzymes)
Plasma No
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375 Switzerland 2009-2012 Cohorte Lausannoise (CoLaus) Community 40-79 40-79 1,444 1,517 1,444 1,517 1,444 1,517 Enzymatic
Homogeneous assay (alpha-
Cyclodextrin + PEG-coupled 
enzymes)
Plasma No
376 Switzerland 2014-2017 Cohorte Lausannoise (CoLaus) Community 50-79 50-79 722 762 722 761 722 761 Enzymatic
Homogeneous assay (alpha-
Cyclodextrin + PEG-coupled 
enzymes)
Plasma No
377 Thailand 1991
Thailand National Health Examination 
Survey I
National 40-79 40-79 2,508 3,165 Unknown Serum Unknown
378 Thailand 1997
Thailand National Health Examination 
Survey II
National 40-59 40-59 447 689 Unknown Unknown Unknown
379 Thailand 2000 InterASIA National 40-79 40-79 1,739 2,619 Enzymatic Serum Yes (CDC/CRMLN)
380 Thailand 2004
Thailand National Health Examination 
Survey III
National 40-79 40-79 13,645 15,122 Enzymatic Serum Unknown
381 Thailand 2003-2004
The Fifth National Nutrition Survey of 
Thailand
National 40-79 40-79 300 386 Enzymatic Plasma No
382 Thailand 2009
Thailand National Health Examination 
Survey IV 
National 40-79 40-79 6,723 7,424 Enzymatic Serum Unknown
383
United 
Kingdom
1983-1984 MONICA, Belfast Subnational 40-59 40-59 605 610 594 598 592 598 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
384
United 
Kingdom
1984-1986 Scottish Heart Health Survey Subnational 40-59 40-59 4,068 3,926 3,870 3,777 3,867 3,774 Enzymatic
Dextran sulphate-Magnesium 
method; Unknown
Serum Yes (other)
385
United 
Kingdom
1986-1987
Dietary and Nutritional Survey of British 
Adults 1986-1987
National 40-59 40-59 385 380 384 380 384 380 Unknown Unknown Serum Unknown
386
United 
Kingdom
1986-1987 MONICA, Belfast Subnational 40-59 40-59 617 611 617 615 614 610 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
387
United 
Kingdom
1987-1988 Edinburgh Artery Study Community 60-69 60-69 429 396 427 396 427 396 Unknown Precipitation; Unknown Serum Yes (WHO-LRC)
388
United 
Kingdom
1991-1992 Health Survey for England National 40-79 40-79 1,389 1,483 Unknown Serum Unknown
389
United 
Kingdom
1991-1992 MONICA, Belfast Subnational 40-59 40-59 545 508 542 508 542 508 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (WHO-LRC)
390
United 
Kingdom
1992 MONICA, Glasgow Community 40-59 40-59 356 358 332 342 332 342 Enzymatic
Dextran sulphate-Magnesium 
method/Phosphotungstate-
Magnesiume (PTA) method; 
Enzymatic
Serum Yes (WHO-LRC)
391
United 
Kingdom
1993 Health Survey for England National 40-79 40-79 3,208 3,453 Unknown Serum Unknown
392
United 
Kingdom
1994 Health Survey for England National 40-79 40-79 2,872 3,269 Enzymatic Serum Yes (other)
393
United 
Kingdom
1995 MONICA, Glasgow Community 40-59 40-59 431 429 412 417 412 417 Enzymatic
Dextran sulphate-Magnesium 
method; Enzymatic
Serum Yes (WHO-LRC)
394
United 
Kingdom
1994-1995
National Diet and Nutrition Survey 
(NDNS)
National 70-79 70-79 280 195 280 196 280 195 Unknown Unknown Plasma Unknown
395
United 
Kingdom
1995 Scottish Health Survey (SHeS) Subnational 40-59 40-59 1,174 1,352 Enzymatic Serum Yes (other)
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396
United 
Kingdom
1998 Health Survey for England National 40-79 40-79 2,969 3,326 2,962 3,317 2,959 3,315 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (other)
397
United 
Kingdom
1998 Scottish Health Survey (SHeS) Subnational 40-69 40-69 1,523 1,811 1,511 1,806 1,511 1,805 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Serum Yes (other)
398
United 
Kingdom
1998-2000 The British Regional Heart Study National 60-79 3,938 3,912 3,912 Enzymatic
Homogeneous assay (alpha-
Cyclodextrin + PEG-coupled 
enzymes)
Serum Unknown
399
United 
Kingdom
1999-2001 British Women's Heart and Health Study National 60-79 3,697 3,691 3,691 Unknown Precipitation; Unknown Serum Unknown 5
400
United 
Kingdom
2000 Health Survey for England National 70-79 70-79 73 78 68 72 68 72 Unknown Unknown Unknown Unknown
401
United 
Kingdom
1999-2004 Hertfordshire Cohort Study Subnational 60-69 60-69 1,324 1,161 1,324 1,161 1,324 1,161 Enzymatic Unknown Serum Unknown
402
United 
Kingdom
2000-2001
National Diet and Nutrition Survey 2000-
2001
National 40-59 40-59 273 306 272 306 272 306 Enzymatic
Phosphotungstate-Magnesium 
(PTA) method; Enzymatic
Plasma Yes (other)
403
United 
Kingdom
2003 The European Male Ageing Study Community 40-79 396 396 396 Unknown Unknown Unknown Unknown
404
United 
Kingdom
2003 Health Survey for England National 40-79 40-79 2,439 2,837 2,440 2,837 2,439 2,837 Enzymatic
Homogeneous assay (Antibody, 
two reagents)
Serum Yes (other)
405
United 
Kingdom
2003 Scottish Health Survey (SHeS) Subnational 40-79 40-79 1,290 1,502 1,291 1,502 1,290 1,502 Enzymatic Homogeneous assay Serum Yes (other)
406
United 
Kingdom
2004-2005
English Longitudinal Study of Ageing 
Wave 2 2004-2005
National 60-79 60-79 1,594 1,819 1,592 1,819 1,592 1,819 Enzymatic
Homogeneous assay (Antibody, 
two reagents)
Serum Yes (other)
407
United 
Kingdom
2005 Health Survey for England National 70-79 70-79 487 563 487 563 487 563 Enzymatic
Homogeneous assay (Antibody, 
two reagents)
Serum Yes (other)
408
United 
Kingdom
2006 Health Survey for England National 40-79 40-79 2,274 2,666 2,275 2,666 2,274 2,666 Enzymatic
Homogeneous assay (Antibody, 
two reagents)
Serum Yes (other)
409
United 
Kingdom
2008 The European Male Ageing Study Community 40-79 284 280 280 Unknown Unknown Unknown Unknown
410
United 
Kingdom
2008 Health Survey for England National 40-79 40-79 2,241 2,621 2,241 2,620 2,241 2,620 Enzymatic
Homogeneous assay (Antibody, 
two reagents)
Serum Yes (other)
411
United 
Kingdom
2008 Scottish Health Survey (SHeS) Subnational 40-79 40-79 289 321 289 321 289 321 Enzymatic Homogeneous assay Serum Yes (other)
412
United 
Kingdom
2008-2009
English Longitudinal Study of Ageing 
Wave 4 2008-2009
National 50-79 50-79 2,657 3,173 2,655 3,170 2,655 3,170 Enzymatic
Homogeneous assay (Antibody, 
two reagents)
Serum Yes (other)
413
United 
Kingdom
2009 Health Survey for England National 40-79 40-79 736 813 736 813 736 813 Enzymatic
Homogeneous assay (Antibody, 
two reagents)
Serum Yes (other)
414
United 
Kingdom
2009 Scottish Health Survey (SHeS) Subnational 40-79 40-79 255 317 255 317 255 317 Enzymatic Homogeneous assay Serum Yes (other)
415
United 
Kingdom
2010 Health Survey for England National 40-79 40-79 1,135 1,447 1,135 1,447 1,135 1,447 Enzymatic Homogeneous assay Serum Yes (other)
416
United 
Kingdom
2008-2012
National Diet and Nutrition Survey 
(NDNS)
National 40-79 40-79 294 390 294 390 294 390 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (other)
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417
United 
Kingdom
2010 Scottish Health Survey (SHeS) Subnational 40-79 40-79 239 304 239 304 239 304 Enzymatic Homogeneous assay Serum Yes (other)
418
United 
Kingdom
2011 Health Survey for England National 40-79 40-79 1,178 1,458 1,177 1,458 1,176 1,458 Enzymatic Homogeneous assay Serum Yes (other)
419
United 
Kingdom
2011 Scottish Health Survey (SHeS) Subnational 40-79 40-79 230 258 230 258 230 258 Enzymatic Homogeneous assay Serum Yes (other)
420
United 
Kingdom
2012 Health Survey for England National 40-79 40-79 1,236 1,492 1,233 1,492 1,233 1,492 Enzymatic Homogeneous assay Serum Yes (other)
421
United 
Kingdom
2012-2013
English Longitudinal Study of Ageing 
Wave 6 2012-2013
National 50-79 50-79 2,496 3,030 2,494 3,029 2,494 3,029 Enzymatic Homogeneous assay Serum Yes (other)
422
United 
Kingdom
2013 Health Survey for England National 40-79 40-79 1,426 1,627 1,424 1,626 1,424 1,626 Enzymatic Homogeneous assay Serum Yes (other)
423
United 
Kingdom
2014 Health Survey for England National 40-79 40-79 1,228 1,423 1,229 1,423 1,228 1,423 Enzymatic Homogeneous assay Serum Yes (other)
424
United 
Kingdom
2013-2014
National Diet and Nutrition Survey 
(NDNS)
National 40-79 40-79 199 286 199 286 199 286 Enzymatic
Homogeneous assay 
(Accelerator Selective 
Detergent; Enzymatic)
Serum Yes (other)
425
United 
Kingdom
2015 Health Survey for England National 40-79 40-79 1,217 1,477 1,217 1,478 1,217 1,477 Enzymatic Homogeneous assay Serum Yes (other)
426
United 
Kingdom
2016 Health Survey for England National 40-79 40-79 1,183 1,441 1,183 1,441 1,183 1,441 Enzymatic Homogeneous assay Serum Yes (other)
427
United States 
of America
1971-1975 US NHANES I National 40-69 40-69 3,435 4,303 Unknown Serum Yes (CDC/CRMLN)
428
United States 
of America
1976-1980 US NHANES II National 40-69 40-69 2,965 3,288 2,374 2,703 2,374 2,703 LRC method
Heparin-Manganese method; 
LRC method
Serum Yes (CDC/CRMLN)
429
United States 
of America
1979-1980 MONICA, Stanford Subnational 40-59 40-59 277 345 276 344 276 344 Extraction
Heparin-Manganese method; 
Direct
Plasma Yes (WHO-LRC) 6
430
United States 
of America
1985-1986 MONICA, Stanford Subnational 40-59 40-59 267 314 267 314 267 314 Extraction
Heparin-Manganese method; 
Extraction
Plasma Yes (WHO-LRC) 6
431
United States 
of America
1987-1989
Atherosclerosis Risk in Communities 
Study 
Subnational 50-59 50-59 2,460 3,006 2,458 3,006 2,458 3,006 Enzymatic
Dextran sulphate-Magnesium 
method; Enzymatic
Plasma Yes (CDC/CRMLN)
432
United States 
of America
1989-1990 Cardiovascular Health Study Subnational 70-79 70-79 1,195 1,511 1,193 1,510 1,192 1,510 Enzymatic
Dextran sulphate-Magnesium 
method; Enzymatic
Plasma Yes (other)
433
United States 
of America
1989-1990 MONICA, Stanford Subnational 40-59 40-59 263 326 263 325 263 325 Enzymatic
Dextran sulphate-Magnesium 
method; Direct/Enzymatic
Plasma Yes (WHO-LRC) 6
434
United States 
of America
1990-1992
Atherosclerosis Risk in Communities 
Study 
Subnational 50-69 50-69 4,018 4,897 4,000 4,868 3,999 4,868 Enzymatic
Dextran sulphate-Magnesium 
method; Enzymatic
Plasma Yes (CDC/CRMLN)
435
United States 
of America
1988-1994 US NHANES III National 40-79 40-79 3,946 4,301 3,905 4,261 3,903 4,260 Enzymatic
Heparin-Manganese method; 
Enzymatic
Serum Yes (CDC/CRMLN)
436
United States 
of America
1992-1993 Cardiovascular Health Study Subnational 70-79 70-79 1,226 1,695 1,222 1,694 1,222 1,694 Enzymatic
Dextran sulphate-Magnesium 
method; Enzymatic
Plasma Yes (other)
437
United States 
of America
1993-1995
Atherosclerosis Risk in Communities 
Study 
Subnational 50-69 50-69 3,804 4,824 3,800 4,821 3,800 4,821 Enzymatic
Dextran sulphate-Magnesium 
method; Enzymatic
Plasma Yes (CDC/CRMLN)
438
United States 
of America
1993-1994 Cardiovascular Health Study Subnational 70-79 70-79 1,243 1,776 Enzymatic Plasma Yes (other)
439
United States 
of America
1994-1995 Cardiovascular Health Study Subnational 70-79 70-79 1,170 1,707 Enzymatic Plasma Yes (other)
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440
United States 
of America
1996-1998
Atherosclerosis Risk in Communities 
Study 
Subnational 50-69 50-69 2,896 3,789 2,895 3,788 2,895 3,788 Enzymatic
Dextran sulphate-Magnesium 
method; Enzymatic
Plasma Yes (CDC/CRMLN)
441
United States 
of America
1996-1997 Cardiovascular Health Study Subnational 70-79 70-79 936 1,418 Enzymatic Plasma Yes (other)
442
United States 
of America
1996-1997
Study of Women's Health Across the 
Nation
Subnational 40-49 2,862 2,862 2,862 Enzymatic
Heparin-Manganese method; 
Enzymatic
Plasma Yes (CDC/CRMLN) 7
443
United States 
of America
1997-1998 Cardiovascular Health Study Subnational 70-79 70-79 694 1,125 Enzymatic Plasma Yes (other)
444
United States 
of America
1997-1999
Study of Women's Health Across the 
Nation
Subnational 40-49 2,202 2,199 2,199 Enzymatic
Heparin-Manganese method; 
Enzymatic
Plasma Yes (CDC/CRMLN) 7
445
United States 
of America
1999-2000 US NHANES 1999-2000 National 40-79 40-79 1,165 1,200 1,163 1,199 1,163 1,198 Enzymatic
Heparin-Manganese method; 
Enzymatic and Homogeneous 
assay (alpha-Cyclodextrin + 
PEG-coupled enzymes)
Serum Yes (CDC/CRMLN)
446
United States 
of America
1999-2001
Study of Women's Health Across the 
Nation
Subnational 40-49 1,364 1,362 1,362 Enzymatic
Heparin-Manganese method; 
Enzymatic
Plasma Yes (CDC/CRMLN) 7
447
United States 
of America
2000-2002
Study of Women's Health Across the 
Nation
Subnational 40-49 1,043 1,043 1,043 Enzymatic
Heparin-Manganese method; 
Enzymatic
Plasma Yes (CDC/CRMLN) 7
448
United States 
of America
2001-2002 US NHANES 2001-2002 National 40-79 40-79 1,349 1,267 1,349 1,267 1,349 1,267 Enzymatic
Heparin-Manganese method; 
Enzymatic and Homogeneous 
assay (alpha-Cyclodextrin + 
PEG-coupled enzymes)
Serum Yes (CDC/CRMLN)
449
United States 
of America
2003-2004 US NHANES 2003-2004 National 40-79 40-79 1,257 1,252 1,257 1,252 1,257 1,252 Enzymatic
Homogeneous assay (alpha-
Cyclodextrin + PEG-coupled 
enzymes)
Serum Yes (CDC/CRMLN)
450
United States 
of America
2005-2006
Coronary Artery Risk Development in 
Young Adults (CARDIA)
Subnational 40-49 40-49 1,237 1,549 1,236 1,549 1,235 1,549 Enzymatic
Dextran sulphate-Magnesium 
method; Enzymatic
Plasma Unknown
451
United States 
of America
2005-2006 Cardiovascular Health Study Subnational 70-79 70-79 266 495 266 495 266 495 Enzymatic
Dextran sulphate-Magnesium 
method; Enzymatic
Plasma Yes (other)
452
United States 
of America
2005-2006 US NHANES 2005-2006 National 40-79 40-79 1,247 1,203 1,247 1,203 1,247 1,203 Enzymatic
Homogeneous assay (alpha-
Cyclodextrin + PEG-coupled 
enzymes)
Serum Yes (CDC/CRMLN)
453
United States 
of America
2007-2008 US NHANES 2007-2008 National 40-79 40-79 1,617 1,659 1,511 1,536 1,511 1,536 Enzymatic
Homogeneous assay (Dextran 
sulphate-Magnesium + PEG-
coupled enzymes)
Serum Yes (CDC/CRMLN)
454
United States 
of America
2009-2010 US NHANES 2009-2010 National 40-79 40-79 1,692 1,730 1,691 1,730 1,691 1,730 Enzymatic
Homogeneous assay (Dextran 
sulphate-Magnesium + PEG-
coupled enzymes)
Serum Yes (CDC/CRMLN)
455
United States 
of America
2011-2013
Atherosclerosis Risk in Communities 
Study 
Subnational 70-79 70-79 1,172 1,639 1,172 1,639 1,172 1,639 Enzymatic Homogeneous assay Plasma Yes (CDC/CRMLN)
456
United States 
of America
2011-2012 US NHANES 2011-2012 National 40-79 40-79 1,417 1,455 1,417 1,455 1,417 1,455 Enzymatic
Homogeneous assay (Dextran 
sulphate-Magnesium + PEG-
coupled enzymes)
Serum Yes (CDC/CRMLN)
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457
United States 
of America
2013-2014 US NHANES 2013-2014 National 40-79 40-79 1,523 1,697 1,523 1,698 1,523 1,697 Enzymatic
Homogeneous assay (Dextran 
sulphate-Magnesium + PEG-
coupled enzymes)
Serum Yes (CDC/CRMLN)
458
United States 
of America
2015-2016 US NHANES 2015-2016 National 40-79 40-79 1,498 1,599 1,497 1,598 1,497 1,598 Enzymatic
Homogeneous assay (Dextran 
sulphate-Magnesium + PEG-
coupled enzymes)
Serum Yes (CDC/CRMLN)
1. Data were available only as summary statistics, which did not include mean total-to-HDL cholesterol ratio.
2. Electrophoresis was used for measuring lipid fractions. As this method may be inaccurate in quantifying lipid fractions, mean HDL and non-HDL cholesterol and mean total-to-HDL cholesterol ratio were not included in this analysis.
3. Lipid fractions were measured only since 2009. As nationally representative health examination surveys measured lipid fractions almost every year since 1998 we excluded this data from the analysis.
4. This research uses data from China Health and Nutrition Survey (CHNS). We thank the National Institute of Nutrition and Food Safety, China Center for Disease Control and Prevention, Carolina Population Center (5 R24 HD050924), the University of North Carolina at Chapel Hill, the 
NIH (R01‐HD30880, DK056350, R24-HD050924, and R01‐HD38700) and the Fogarty International Center, NIH for financial support for the CHNS data collection and analysis files from 1989 to 2011 and future surveys, and the China‐Japan Friendship Hospital, Ministry of Health for 
support for CHNS 2009.
5. The British Women’s Heart and Health Study is supported by the British Heart Foundation (PG/13/66/30442). British Women’s Heart and Health Study data are available to bona fide researchers for research purposes. Please refer to the BWHHS data sharing policy at 
http://www.ucl.ac.uk/british-womens-heart-health-study.
6. We thank Prof Stephen Fortmann for data from the Stanford Five-City Project.
7. The bibliographic citation for this data source is: Sutton-Tyrrell, Kim, Faith Selzer, MaryFran Sowers, Robert Neer, Lynda Powell, Ellen Gold, Gail Greendale, Gerson Weiss, Karen Matthews, and Sonja McKinlay. Study of Women's Health Across the Nation (SWAN), 1996-1997: Baseline 
Dataset. ICPSR28762-v2. Ann Arbor, MI: Inter-university Consortium for Political and Social Research[distributor], 2014-02-04. http://doi.org/10.3886/ICPSR28762.v2
Participating to a lipid standardisation programme or quality control schemes abbreviations: CDC/CRMLN = CDC/Cholesterol Reference Method Laboratory Network Lipid Standardization Program; Other = Participation in internal and external quality control schemes; WHO-LRC = WHO 
Regional Lipid Reference Centre in Prague; Unknown = Information unavailable or lipids measured in multiple laboratories.
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Supplementary Table 2: Data availability by country for ages 40-59 years. 
Country (abbreviation) 
Total cholesterol Non-HDL and HDL cholesterol 
Start year End year Number of data sources Start year End year 
Number of 
data sources 
Australia (AUS) 1980 2012 15 1980 2012 15 
Belgium (BEL) 1984 2015 20 (men) 18 (women) 1984 2015 
20 (men) 
18 (women) 
Canada (CAN) 1985 2015 9 1985 2015 9 
China (CHN) 1983 2015 35 (men) 34 (women) 1983 2015 
35 (men) 
34 (women) 
Czech Republic (CZE) 1985 2018 7 1985 2018 7 
Finland (FIN) 1972 2012 15 (men) 12 (women) 1982 2012 10 
France (FRA) 1985 2013 13 (men) 12 (women) 1985 2013 
13 (men) 
12 (women) 
Germany (DEU) 1982 2012 39 1982 2012 36 
Iceland (ISL) 1970/1971* 2012 12 1983 2012 9 
Italy (ITA) 1982 2012 23 (men) 21 (women) 1982 2012 
23 (men) 
21 (women) 
Japan (JPN) 1980 2016 56 1980 2016 52 
Lithuania (LTU) 1972/1983* 2008 11 (men) 9 (women) 1983 2008 9 
New Zealand (NZL) 1982 2009 6 1982 2009 5 
Norway (NOR) 1979 2008 7 1979 2008 7 
Poland (POL) 1983 2016 22 (men) 20 (women) 1983 2016 
20 (men) 
18 (women) 
Slovakia (SVK) 1993 2012 5 1993 2012 5 
South Korea (KOR) 1998 2016 20 1998 2016 13 
Spain (ESP) 1986 2014 20 (men) 18 (women) 1986 2014 
18 (men) 
16 (women) 
Sweden (SWE) 1985 2014 14 (men) 12 (women) 
Switzerland (CHE) 1984 2017 7 1984 2017 7 
Thailand (THA) 1991 2009 6 
United Kingdom (GBR) 1983 2016 36 (men) 34 (women) 1983 2016 
32 (men) 
30 (women) 
United States of America 
(USA) 1971 2016 
20 (men) 
24 (women) 1976 2016 
19 (men) 
23 (women) 
* Data were available from 1970 for men and from 1971 for women (Iceland), and from 1972 for men and from
1983 for women (Lithuania).
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Supplementary Table 3: Change per decade in mean total cholesterol by sex in people aged 
40-59 years, shown graphically in Figure 1 in the main paper. Results for each country apply
to its entire period of total cholesterol data availability (Supplementary Table 2). Numbers in 
brackets show 95% confidence intervals. 
Country 
Change per decade in mean total cholesterol (mmol/L) 
Men Women 
Australia -0.18 (-0.22 to -0.14) -0.19 (-0.23 to -0.16)
Belgium -0.37 (-0.41 to -0.32) -0.38 (-0.44 to -0.32)
Canada -0.23 (-0.32 to -0.13) -0.22 (-0.34 to -0.10)
China 0.32 (0.23 to 0.41) 0.27 (0.16 to 0.38) 
Czech Republic -0.34 (-0.41 to -0.27) -0.35 (-0.42 to -0.28)
Finland -0.40 (-0.46 to -0.34) -0.43 (-0.51 to -0.36)
France -0.08 (-0.16 to -0.01) -0.03 (-0.10 to 0.04)
Germany -0.28 (-0.34 to -0.22) -0.28 (-0.34 to -0.23)
Iceland -0.27 (-0.32 to -0.23) -0.33 (-0.37 to -0.28)
Italy -0.12 (-0.19 to -0.05) -0.06 (-0.12 to 0.00)
Japan 0.14 (0.12 to 0.16) 0.13 (0.11 to 0.16) 
Lithuania -0.05 (-0.13 to 0.04) -0.27 (-0.41 to -0.12)
New Zealand -0.08 (-0.24 to 0.08) -0.22 (-0.40 to -0.05)
Norway -0.41 (-0.49 to -0.33) -0.42 (-0.51 to -0.33)
Poland 0.00 (-0.05 to 0.06) -0.02 (-0.08 to 0.03)
Slovakia -0.22 (-0.43 to -0.01) -0.37 (-0.60 to -0.14)
South Korea 0.03 (0.01 to 0.05) 0.04 (0.02 to 0.05) 
Spain -0.16 (-0.22 to -0.11) -0.11 (-0.17 to -0.05)
Sweden -0.30 (-0.43 to -0.17) -0.30 (-0.41 to -0.18)
Switzerland -0.34 (-0.48 to -0.20) -0.27 (-0.40 to -0.14)
Thailand 0.29 (0.22 to 0.36) 0.29 (0.16 to 0.41) 
United Kingdom -0.24 (-0.29 to -0.20) -0.25 (-0.29 to -0.22)
United States of America -0.18 (-0.25 to -0.11) -0.12 (-0.18 to -0.06)
30
Supplementary Table 4: Change per decade in mean HDL and non-HDL cholesterol, and in 
mean total-to-HDL cholesterol ratio by sex in people aged 40-59 years, shown graphically in 
Figure 2 and Figure 4 in the main paper. Results for each country apply to its period of HDL 
and non-HDL cholesterol data availability (Supplementary Table 2). Numbers in brackets show 
95% confidence intervals. 
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 Country 
Change per decade in mean HDL cholesterol 
(mmol/L) 
Change per decade in mean non-HDL 
cholesterol (mmol/L) 
Change per decade in mean total-to-HDL 
cholesterol ratio 
Men Women Men Women Men Women 
Australia 0.013 (-0.001 to 0.027) 0.010 (-0.003 to 0.024) -0.20 (-0.24 to -0.15) -0.20 (-0.24 to -0.17) -0.26 (-0.33 to -0.18) -0.18 (-0.23 to -0.13) 
Belgium 0.045 (0.014 to 0.077) 0.036 (0.004 to 0.067) -0.41 (-0.47 to -0.36) -0.43 (-0.48 to -0.37) -0.55 (-0.67 to -0.43) -0.38 (-0.45 to -0.30) 
Canada -0.005 (-0.025 to 0.014) -0.006 (-0.032 to 0.020) -0.23 (-0.31 to -0.15) -0.21 (-0.31 to -0.11) -0.25 (-0.35 to -0.16) -0.15 (-0.22 to -0.08) 
China 0.034 (0.001 to 0.067) -0.006 (-0.045 to 0.033) 0.30 (0.23 to 0.38) 0.25 (0.16 to 0.34) 0.21 (0.14 to 0.27) 0.21 (0.14 to 0.28) 
Czech Republic -0.015 (-0.033 to 0.003) 0.040 (0.012 to 0.067) -0.33 (-0.41 to -0.25) -0.41 (-0.49 to -0.34) -0.23 (-0.32 to -0.14) -0.31 (-0.37 to -0.25) 
Finland 0.038 (0.018 to 0.058) 0.043 (0.014 to 0.072) -0.34 (-0.43 to -0.25) -0.34 (-0.43 to -0.24) -0.42 (-0.53 to -0.32) -0.31 (-0.40 to -0.21) 
France 0.020 (-0.011 to 0.050) 0.017 (-0.028 to 0.062) -0.10 (-0.15 to -0.05) -0.03 (-0.09 to 0.03) -0.14 (-0.23 to -0.06) -0.07 (-0.14 to 0.00) 
Germany -0.041 (-0.069 to -0.013) -0.041 (-0.075 to -0.006) -0.23 (-0.30 to -0.17) -0.24 (-0.28 to -0.19) -0.07 (-0.19 to 0.05) -0.08 (-0.15 to 0.00) 
Iceland 0.029 (0.008 to 0.051) 0.065 (0.038 to 0.091) -0.44 (-0.54 to -0.33) -0.53 (-0.61 to -0.46) -0.42 (-0.56 to -0.29) -0.45 (-0.54 to -0.36) 
Italy 0.021 (-0.004 to 0.046) 0.084 (0.050 to 0.118) -0.13 (-0.20 to -0.07) -0.13 (-0.19 to -0.07) -0.22 (-0.31 to -0.12) -0.21 (-0.30 to -0.13) 
Japan 0.088 (0.080 to 0.096) 0.168 (0.153 to 0.182) 0.02 (-0.01 to 0.04) -0.08 (-0.11 to -0.06) -0.16 (-0.19 to -0.13) -0.27 (-0.29 to -0.24) 
Lithuania 0.048 (-0.016 to 0.112) 0.025 (-0.041 to 0.092) -0.27 (-0.39 to -0.15) -0.38 (-0.50 to -0.26) -0.35 (-0.53 to -0.16) -0.34 (-0.51 to -0.17) 
New Zealand 0.118 (0.093 to 0.143) 0.136 (0.110 to 0.162) -0.16 (-0.30 to -0.02) -0.30 (-0.46 to -0.14) -0.61 (-0.78 to -0.45) -0.53 (-0.70 to -0.36) 
Norway -0.080 (-0.122 to -0.038) -0.095 (-0.162 to -0.027) -0.33 (-0.40 to -0.26) -0.33 (-0.42 to -0.25) -0.07 (-0.21 to 0.07) -0.08 (-0.25 to 0.08) 
Poland -0.033 (-0.070 to 0.003) 0.026 (-0.017 to 0.070) 0.01 (-0.04 to 0.07) -0.06 (-0.10 to -0.01) 0.07 (-0.05 to 0.19) -0.07 (-0.16 to 0.03) 
Slovakia -0.051 (-0.101 to -0.002) 0.005 (-0.038 to 0.048) -0.16 (-0.38 to 0.07) -0.37 (-0.60 to -0.15) -0.02 (-0.40 to 0.36) -0.28 (-0.49 to -0.06) 
South Korea 0.035 (0.000 to 0.070) 0.093 (0.056 to 0.130) -0.01 (-0.06 to 0.05) -0.04 (-0.09 to 0.00) -0.10 (-0.22 to 0.01) -0.25 (-0.34 to -0.16) 
Spain 0.020 (-0.012 to 0.052) 0.047 (0.005 to 0.090) -0.19 (-0.25 to -0.12) -0.16 (-0.23 to -0.09) -0.28 (-0.40 to -0.15) -0.23 (-0.34 to -0.12) 
Switzerland 0.096 (0.038 to 0.154) 0.152 (0.079 to 0.225) -0.42 (-0.57 to -0.26) -0.40 (-0.55 to -0.25) -0.65 (-0.90 to -0.41) -0.49 (-0.67 to -0.31) 
United Kingdom 0.093 (0.073 to 0.113) 0.111 (0.089 to 0.132) -0.28 (-0.32 to -0.24) -0.33 (-0.37 to -0.29) -0.59 (-0.67 to -0.50) -0.47 (-0.53 to -0.41) 
United States of America 0.024 (0.012 to 0.035) 0.035 (0.020 to 0.050) -0.20 (-0.27 to -0.12) -0.10 (-0.17 to -0.03) -0.24 (-0.34 to -0.14) -0.13 (-0.20 to -0.06) 
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Supplementary Figure 1: The association between mean LDL and non-HDL cholesterol in 
studies with data on both variables. Each data point is one study-sex-age group. 
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Supplementary Figure 2: Measurement methods and participation in a lipid standardisation 
programme in studies with data on HDL cholesterol. 
HDL cholesterol measurement method abbreviations: AB = Antibody, two reagents; ASD = 
Accelerator Selective Detergent; CAT = Catalase; DS = Dextran sulphate-Mg2+; HC = 
Heparin-Ca2+; HM = Heparin-Mn2+; IE = Immuno-enzymatic; Other = Homogeneous assay: 
details unavailable or multiple homogeneous assays used, Precipitation: details unavailable or 
multiple methods used; PEG = Homogeneous assay: Polyethylene glycol-modified enzymes, 
Precipitation: Polyethylene glycol; PEG + Cyc = Polyethylene glycol-modified enzymes with 
cyclodextrin; PEG + DS = Polyethylene glycol-modified enzymes with dextran sulphate-Mg2+; 
PTA = Phosphotungstate-Mg2+; Unknown = Information unavailable or multiple methods 
used. 
Lipid standardisation abbreviations: CDC/CRMLN = CDC/Cholesterol Reference Method 
Laboratory Network Lipid Standardization Program; Other = Participation in internal and 
external quality control schemes; WHO-LRC = WHO Regional Lipid Reference Centre in 
Prague; Unknown = Information unavailable or lipids measured in multiple laboratories. 
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Supplementary Figure 3: Linear and nonlinear (LOESS) regression fits by country, sex and 
age group. 
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Supplementary Figure 4: Mean total cholesterol at the beginning and end of analysis period 
by country and sex in people aged 40 to 59 years. The dark lines show the results for the period 
of data availability for each country (Supplementary Table 2); the lighter segments extend the 
trends to the period from 1980 to 2015 so that the start and end years are comparable across 
countries. 
* Finland, Iceland, Lithuania, Norway and USA had data prior to 1980 and Czech Republic,
Japan, Poland, South Korea, Switzerland, UK and USA after 2015. This figure shows results 
from 1980 to 2015 so that the start and end years are comparable across countries. 
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Supplementary Figure 5: Mean (A) non-HDL and (B) HDL cholesterol at the beginning and 
end of analysis period by country and sex in people aged 40 to 59 years. The dark lines show 
the results for the period of data availability for each country (Supplementary Table 2); the 
lighter segments extend the trends to the period from 1980 to 2015 so that the start and end 
years are comparable across countries. 
 
* Norway and USA had data prior to 1980 and Czech Republic, Japan, Poland, South Korea, 
Switzerland, UK and USA after 2015. This figure shows results from 1980 to 2015 so that the 
start and end years are comparable across countries. 
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Supplementary Figure 6: Mean total-to-HDL cholesterol ratio at the beginning and end of 
analysis period by country and sex in people aged 40 to 59 years. The dark lines show the 
results for the period of data availability for each country (Supplementary Table 2); the lighter 
segments extend the trends to the period from 1980 to 2015 so that the start and end years are 
comparable across countries. 
 
* Norway and USA had data prior to 1980 and Czech Republic, Japan, Poland, South Korea, 
Switzerland, UK and USA after 2015. This figure shows results from 1980 to 2015 so that the 
start and end years are comparable across countries. 
  
86
Japan*
Belgium
Switzerland*
UK*
Lithuania
China
New Zealand
Iceland
Finland
Italy
Poland*
Spain
Australia
South Korea*
Canada
USA*
France
Czech Republic*
Slovakia
Germany
Norway*
2.8 3.3 3.8 4.3 4.8 5.3 5.8 6.3
Mean total−to−HDL cholesterol ratio
Men
Japan*
Switzerland*
Iceland
Belgium
New Zealand
UK*
Finland
Italy
Czech Republic*
Australia
Spain
Lithuania
USA*
Canada
Poland*
France
Germany
Slovakia
South Korea*
China
Norway*
2.8 3.3 3.8 4.3 4.8 5.3 5.8 6.3
Mean total−to−HDL cholesterol ratio
Nordic countries
Eastern Central Europe
Western Central Europe
Southern Europe
High−income English−speaking countries
East and southeast Asia
Women
87
Supplementary Figure 7: Change per decade in mean (A) total cholesterol, (B) non-HDL 
cholesterol and (C) HDL cholesterol in people aged 40-59 years unadjusted versus adjusted for 
plasma-serum differences. 
AUS = Australia; BEL = Belgium; CAN = Canada; CHE = Switzerland; CHN = China; CZE 
= Czech Republic; DEU = Germany; ESP = Spain; FIN = Finland; FRA = France; GBR = 
United Kingdom; ISL = Iceland; ITA = Italy; JPN = Japan; KOR = South Korea; LTU = 
Lithuania; NOR = Norway; NZL = New Zealand; POL = Poland; SVK = Slovakia; SWE = 
Sweden; THA = Thailand; USA = United States of America. 
88
ll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
AUS
BEL
CAN
CHN
CZE
FIN
FRA
DEU
ISL
ITA
JPN
LTU
NZL
NOR
POL
SVK
KOR
ESP
SWE
CHE
THA
GBR
USA
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
AUS
BEL
CAN
CHN
CZE
FIN
FRA
DEU
ISL
ITA
JPN
LTU
NZL
NOR
POL
SVK
KOR
ESP
SWE
CHE
THA
GBR
USA
Men Women
−0.4 −0.2 0.0 0.2 0.4 −0.4 −0.2 0.0 0.2 0.4
−0.4
−0.2
0.0
0.2
0.4
Change per decade in mean total cholesterol (mmol/L) 
 unadjusted for plasma−serum differences
Ch
an
ge
 p
er
 d
ec
ad
e 
in
 m
ea
n 
to
ta
l c
ho
le
st
er
ol
 (m
mo
l/L
) 
 
a
dju
ste
d f
o
r 
pl
as
m
a−
se
ru
m
 d
iff
e
re
n
ce
s
l l l l l lNordic countries Eastern central Europe Western central Europe Southern Europe High−income English−speaking countries East and southeast Asia
A
89
ll
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
AUS
BEL
CAN
CHN
CZE
FIN
FRA
DEU
ISL
ITA
JPN
LTU
NZL
NOR
POL
SVK
KOR
ESP
CHE
GBR
USA
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
AUS
BEL
CAN
CHN
CZE
FIN
FRA
DEU
ISL
ITA
JPN
LTU
NZL
NOR
POL
SVK
KOR
ESP
CHE GBR
USA
Men Women
−0.4 −0.2 0.0 0.2 −0.4 −0.2 0.0 0.2
−0.4
−0.2
0.0
0.2
Change per decade in mean non−HDL cholesterol (mmol/L) 
 unadjusted for plasma−serum differences
Ch
an
ge
 p
er
 d
ec
ad
e 
in
 m
ea
n 
no
n−
HD
L 
ch
ol
es
te
ro
l (m
mo
l/L
) 
 
a
dju
ste
d f
o
r 
pl
as
m
a−
se
ru
m
 d
iff
e
re
n
ce
s
l l l l l lNordic countries Eastern central Europe Western central Europe Southern Europe High−income English−speaking countries East and southeast Asia
B
90
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
AUS
BEL
CAN
CHN
CZE
FIN
FRA
DEU
ISL
ITA
JPN
LTU
NZL
NOR
POLSVK
KOR
ESP
CHE
GBR
USA
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
AUS
BEL
CAN
CHN
CZE
FIN
FRA
DEU
ISL
ITA
JPN
LTU
NZL
NOR
POLSVK
KOR
ESP
CHE
GBR
USA
Men Women
−0.1 0.0 0.1 0.2 −0.1 0.0 0.1 0.2
−0.1
0.0
0.1
0.2
Change per decade in mean HDL cholesterol (mmol/L) 
 unadjusted for plasma−serum differences
Ch
an
ge
 p
er
 d
ec
ad
e 
in
 m
ea
n 
HD
L 
ch
ol
es
te
ro
l (m
mo
l/L
) 
 
a
dju
ste
d f
o
r 
pl
as
m
a−
se
ru
m
 d
iff
e
re
n
ce
s
l l l l l lNordic countries Eastern central Europe Western central Europe Southern Europe High−income English−speaking countries East and southeast Asia
C
91
